What genetics tells us about the causes and mechanisms of Parkinson's disease.

Parkinson's disease (PD) is a common motor disorder of mysterious etiology. It is due to the progressive degeneration of the dopaminergic neurons of the substantia nigra and is accompanied by the appearance of intraneuronal inclusions enriched in α-synuclein, the Lewy bodies. It is becoming increasingly clear that genetic factors contribute to its complex pathogenesis. Over the past decade, the genetic basis of rare PD forms with Mendelian inheritance, representing no more than 10% of the cases, has been investigated. More than 16 loci and 11 associated genes have been identified so far; genome-wide association studies have provided convincing evidence that polymorphic variants in these genes contribute to sporadic PD. The knowledge acquired of the functions of their protein products has revealed pathways of neurodegeneration that may be shared between inherited and sporadic PD. An impressive set of data in different model systems strongly suggest that mitochondrial dysfunction plays a central role in clinically similar, early-onset autosomal recessive PD forms caused by parkin and PINK1, and possibly DJ-1 gene mutations. In contrast, α-synuclein accumulation in Lewy bodies defines a spectrum of disorders ranging from typical late-onset PD to PD dementia and including sporadic and autosomal dominant PD forms due to mutations in SCNA and LRRK2. However, the pathological role of Lewy bodies remains uncertain, as they may or may not be present in PD forms with one and the same LRRK2 mutation. Impairment of autophagy-based protein/organelle degradation pathways is emerging as a possible unifying but still fragile pathogenic scenario in PD. Strengthening these discoveries and finding other convergence points by identifying new genes responsible for Mendelian forms of PD and exploring their functions and relationships are the main challenges of the next decade. It is also the way to follow to open new promising avenues of neuroprotective treatment for this devastating disorder.

[1]  A. Singleton,et al.  Analysis of an early‐onset Parkinson's disease cohort for DJ‐1 mutations , 2004, Movement disorders : official journal of the Movement Disorder Society.

[2]  Angela C. Poole,et al.  The PINK1/Parkin pathway regulates mitochondrial morphology , 2008, Proceedings of the National Academy of Sciences.

[3]  L. Meijer,et al.  Constitutive Phosphorylation of the Parkinson's Disease Associated α-Synuclein* , 2000, The Journal of Biological Chemistry.

[4]  M. Mattson,et al.  p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism , 2002, Annals of neurology.

[5]  M. Polymeropoulos,et al.  Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients , 2000, Neuroreport.

[6]  R. Nussbaum,et al.  Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6 , 2007, Neurobiology of Disease.

[7]  M. Mena,et al.  Parkin deficiency increases the resistance of midbrain neurons and glia to mild proteasome inhibition: the role of autophagy and glutathione homeostasis , 2009, Journal of neurochemistry.

[8]  M. Farrer,et al.  Spinocerebellar ataxia type 3 phenotypically resembling parkinson disease in a black family. , 2001, Archives of neurology.

[9]  H. Sandoval,et al.  Essential role for Nix in autophagic maturation of erythroid cells , 2008, Nature.

[10]  Jie Shen,et al.  Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress , 2008, Proceedings of the National Academy of Sciences.

[11]  J. Schulz,et al.  Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. , 2005, Human molecular genetics.

[12]  R. Köster,et al.  Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish (Danio rerio). , 2009, Brain : a journal of neurology.

[13]  D. Hernandez,et al.  Lack of G2019S LRRK2 mutation in a cohort of Taiwanese with sporadic Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[14]  G. Dekomien,et al.  Parkin gene variations in late‐onset Parkinson's disease: comparison between Norwegian and German cohorts , 2006, Acta neurologica Scandinavica.

[15]  Isao Nishimura,et al.  Parkin Suppresses Dopaminergic Neuron-Selective Neurotoxicity Induced by Pael-R in Drosophila , 2003, Neuron.

[16]  M. Ueffing,et al.  The Parkinson disease‐associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro , 2009, Journal of neurochemistry.

[17]  Sebastian Brandner,et al.  Neuroprotective Role of the Reaper-Related Serine Protease HtrA2/Omi Revealed by Targeted Deletion in Mice , 2004, Molecular and Cellular Biology.

[18]  B. Oostra,et al.  The LRRK2 Arg1628Pro variant is a risk factor for Parkinson’s disease in the Chinese population , 2008, Neurogenetics.

[19]  A. Brice,et al.  Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic function , 2005, Journal of neurochemistry.

[20]  Yu Kyeong Kim,et al.  Importance of low-range CAG expansion and CAA interruption in SCA2 Parkinsonism. , 2007, Archives of neurology.

[21]  N. Wood,et al.  PINK1 function in health and disease , 2009, EMBO molecular medicine.

[22]  Patrik Brundin,et al.  Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. , 2002, Nature reviews. Neuroscience.

[23]  D. D. De Silva,et al.  PINK1 mutations in sporadic early‐onset Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[24]  J. Nutt,et al.  SCA2 may present as levodopa‐responsive parkinsonism , 2003, Movement disorders : official journal of the Movement Disorder Society.

[25]  M. Ronaghi,et al.  Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays. , 2008, American journal of human genetics.

[26]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[27]  C. Sander,et al.  Somatic mutations of the Parkinson's disease–associated gene PARK2 in glioblastoma and other human malignancies , 2010, Nature Genetics.

[28]  K. Marder,et al.  Frequency of LRRK2 mutations in early- and late-onset Parkinson disease , 2006, Neurology.

[29]  E. Masliah,et al.  Phosphorylation of Synucleins by Members of the Polo-like Kinase Family* , 2009, The Journal of Biological Chemistry.

[30]  D. Maraganore,et al.  A Genomic Pathway Approach to a Complex Disease: Axon Guidance and Parkinson Disease , 2007, PLoS genetics.

[31]  Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation , 2005, Neurology.

[32]  A. Quattrone,et al.  Compound heterozygosity in DJ-1 gene non-coding portion related to parkinsonism. , 2009, Parkinsonism & related disorders.

[33]  A. Deutch,et al.  Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration , 2007, Brain Research.

[34]  Yan Liu,et al.  LRRK2 R1628P contributes to Parkinson's disease susceptibility in Chinese Han populations from mainland China , 2009, Brain Research.

[35]  A. Brice,et al.  Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity. , 2006, Human molecular genetics.

[36]  A. Bentivoglio,et al.  Prevalence of spinocerebellar ataxia type 2 mutation among Italian Parkinsonian patients , 2007, Movement disorders : official journal of the Movement Disorder Society.

[37]  A. Brice,et al.  α-Synuclein gene duplication is present in sporadic Parkinson disease , 2008, Neurology.

[38]  P. Stanzione,et al.  Frequency and phenotypes of LRRK2 G2019S mutation in Italian patients with Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[39]  V. Hristova,et al.  Identification of a Novel Zn2+-binding Domain in the Autosomal Recessive Juvenile Parkinson-related E3 Ligase Parkin* , 2009, Journal of Biological Chemistry.

[40]  Specificity and Regulation of Casein Kinase-Mediated Phosphorylation of &agr;-Synuclein , 2008 .

[41]  J. Jankovic,et al.  A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease. , 2008, Parkinsonism & related disorders.

[42]  D. Price,et al.  Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. , 2006, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[43]  H. Fung,et al.  The need for appropriate genotyping strategies for glucocerebrosidase mutations in cohorts with Parkinson disease. , 2008, Archives of Neurology.

[44]  G. Hadjigeorgiou,et al.  Mutated α-synuclein gene in two Greek kindreds with familial PD: Incomplete penetrance? , 1999, Neurology.

[45]  B. E. Staveley,et al.  Mutant alpha-synuclein-induced degeneration is reduced by parkin in a fly model of Parkinson's disease. , 2006, Genome.

[46]  L. Stefanis,et al.  Proteasomal Inhibition-Induced Inclusion Formation and Death in Cortical Neurons Require Transcription and Ubiquitination , 2002, Molecular and Cellular Neuroscience.

[47]  N. Ip,et al.  The emerging role of autophagy in Parkinson's disease , 2009, Molecular Brain.

[48]  M. MacDonald,et al.  PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study. , 2002, American journal of human genetics.

[49]  A. Mubaidin,et al.  Pallido‐pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor‐Rakeb syndrome , 1994, Acta neurologica Scandinavica.

[50]  L. Chin,et al.  Ubiquitination of α-synuclein by Siah-1 promotes α-synuclein aggregation and apoptotic cell death , 2007 .

[51]  Heidi Phillips,et al.  Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System , 2000, Neuron.

[52]  E. Tolosa,et al.  Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study , 2008, The Lancet Neurology.

[53]  N. Hattori,et al.  PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy , 2010, The Journal of cell biology.

[54]  S. Itohara,et al.  Pael receptor induces death of dopaminergic neurons in the substantia nigra via endoplasmic reticulum stress and dopamine toxicity, which is enhanced under condition of parkin inactivation. , 2007, Human molecular genetics.

[55]  N. Thakor,et al.  Parkin Facilitates the Elimination of Expanded Polyglutamine Proteins and Leads to Preservation of Proteasome Function* , 2003, Journal of Biological Chemistry.

[56]  A. Ishikawa,et al.  Clinical analysis of 17 patients in 12 Japanese families with autosomal-recessive type juvenile parkinsonism , 1996, Neurology.

[57]  Mark Guttman,et al.  Brain proteasomal function in sporadic Parkinson's disease and related disorders , 2002, Annals of neurology.

[58]  Ivan Dikic,et al.  Atypical ubiquitin chains: new molecular signals , 2008, EMBO reports.

[59]  Nir Giladi,et al.  The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease , 2007, Neurology.

[60]  James Lowe,et al.  Depletion of 26S Proteasomes in Mouse Brain Neurons Causes Neurodegeneration and Lewy-Like Inclusions Resembling Human Pale Bodies , 2008, The Journal of Neuroscience.

[61]  Ann Saada,et al.  The Transgenic Overexpression of α-Synuclein and Not Its Related Pathology Associates with Complex I Inhibition* , 2010, The Journal of Biological Chemistry.

[62]  P. Pástor,et al.  PINK1-linked parkinsonism is associated with Lewy body pathology. , 2010, Brain : a journal of neurology.

[63]  P. Pramstaller,et al.  Association studies of Parkinson's disease and parkin polymorphisms , 2000, Annals of neurology.

[64]  E. Masliah,et al.  Phosphorylation at S87 Is Enhanced in Synucleinopathies, Inhibits α-Synuclein Oligomerization, and Influences Synuclein-Membrane Interactions , 2010, The Journal of Neuroscience.

[65]  Patrizia Rizzu,et al.  Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.

[66]  G. Halliday,et al.  Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. , 2001, Annals of neurology.

[67]  K. Lim,et al.  Jcb: Report , 2022 .

[68]  C. Lautier,et al.  GIGYF2 gene disruption in mice results in neurodegeneration and altered insulin-like growth factor signaling. , 2009, Human molecular genetics.

[69]  C. Chu,et al.  Mitochondrial kinases in Parkinson's disease: converging insights from neurotoxin and genetic models. , 2009, Mitochondrion.

[70]  Ted M. Dawson,et al.  PINK1-dependent recruitment of Parkin to mitochondria in mitophagy , 2009, Proceedings of the National Academy of Sciences.

[71]  N. Hattori,et al.  Mutation analysis for DJ-1 in sporadic and familial parkinsonism: Screening strategy in parkinsonism , 2009, Neuroscience Letters.

[72]  Yi Zhao,et al.  Genetic analysis of SCA2, 3 and 17 in idiopathic Parkinson's disease , 2006, Neuroscience Letters.

[73]  M. Riparbelli,et al.  The Drosophila parkin homologue is required for normal mitochondrial dynamics during spermiogenesis. , 2007, Developmental biology.

[74]  M. Vidailhet,et al.  LOW DISEASE RISK IN RELATIVES OF NORTH AFRICAN LRRK2 PARKINSON DISEASE PATIENTS , 2010, Neurology.

[75]  W. Bender,et al.  A Drosophila model of Parkinson's disease , 2000, Nature.

[76]  A. Parent,et al.  Parkin immunoreactivity in the brain of human and non‐human primates: An immunohistochemical analysis in normal conditions and in Parkinsonian syndromes , 2001, The Journal of comparative neurology.

[77]  Wei Jiang,et al.  Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. , 2009, The Journal of clinical investigation.

[78]  A. Singleton,et al.  Clinical heterogeneity of α‐synuclein gene duplication in Parkinson's disease , 2006 .

[79]  O. Sydow,et al.  S18Y in ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) associated with decreased risk of Parkinson's disease in Sweden. , 2007, Parkinsonism & related disorders.

[80]  R. Nussbaum,et al.  Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.

[81]  W. Parker,et al.  Creation and Characterization of Mitochondrial DNA‐Depleted Cell Lines with “Neuronal‐Like” Properties , 1996, Journal of neurochemistry.

[82]  H. Tanila,et al.  Role of alpha-synuclein in presynaptic dopamine recruitment. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[83]  M. Beal,et al.  Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery , 2008, Proceedings of the National Academy of Sciences.

[84]  T. Meitinger,et al.  The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. , 2006, Human molecular genetics.

[85]  L. Forno,et al.  Neuropathology of Parkinson's Disease , 1996, Journal of neuropathology and experimental neurology.

[86]  J. Obeso,et al.  Analysis of the GIGYF2 gene in familial and sporadic Parkinson disease in the Spanish population , 2010, European journal of neurology.

[87]  M. Rapé,et al.  Building ubiquitin chains: E2 enzymes at work , 2009, Nature Reviews Molecular Cell Biology.

[88]  M. Farrer,et al.  Lrrk2 pathogenic substitutions in Parkinson's disease , 2005, Neurogenetics.

[89]  Mariza de Andrade,et al.  High-resolution whole-genome association study of Parkinson disease. , 2005, American journal of human genetics.

[90]  N. Hattori,et al.  Dopaminergic neuronal dysfunction associated with parkinsonism in both a Gaucher disease patient and a carrier , 2007, Journal of the Neurological Sciences.

[91]  A Dürr,et al.  Causal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.

[92]  J. Langston,et al.  1-Methyl-4-phenylpyridinium ion (MPP+): Identification of a metabolite of MPTP, a toxin selective to the substantia nigra , 1984, Neuroscience Letters.

[93]  M. Canesi,et al.  The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson’s disease and originates from a common ancestor , 2005, Journal of Medical Genetics.

[94]  Li Chen,et al.  α-Synuclein and Parkin Contribute to the Assembly of Ubiquitin Lysine 63-linked Multiubiquitin Chains* , 2005, Journal of Biological Chemistry.

[95]  A. Singleton,et al.  Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. , 2005, Brain : a journal of neurology.

[96]  N. Hattori,et al.  Neuropsychiatric and cognitive features in autosomal‐recessive early parkinsonism due to PINK1 mutations , 2007, Movement disorders : official journal of the Movement Disorder Society.

[97]  A. Singleton,et al.  Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. , 2006, Annals of neurology.

[98]  Peter T Lansbury,et al.  Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. , 2008, The Journal of clinical investigation.

[99]  R. Krüger,et al.  Familial parkinsonism with synuclein pathology , 2001, Neurology.

[100]  P. Lichtner,et al.  PARK11 gene (GIGYF2) variants Asn56Ser and Asn457Thr are not pathogenic for Parkinson's disease. , 2009, Parkinsonism & related disorders.

[101]  A. Reichert,et al.  Loss-of-Function of Human PINK1 Results in Mitochondrial Pathology and Can Be Rescued by Parkin , 2007, The Journal of Neuroscience.

[102]  J. Burgunder,et al.  LRRK2 Gly2385Arg variant is a risk factor of Parkinson’s disease among Han‐Chinese from mainland China , 2008, European journal of neurology.

[103]  Susan Lindquist,et al.  Yeast Genes That Enhance the Toxicity of a Mutant Huntingtin Fragment or α-Synuclein , 2003, Science.

[104]  P. Emson,et al.  Localization of LRRK2 to membranous and vesicular structures in mammalian brain , 2006, Annals of neurology.

[105]  A. Graybiel,et al.  The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. , 1999, Brain : a journal of neurology.

[106]  Sonja W. Scholz,et al.  Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease , 2009, Nature Genetics.

[107]  Jian Feng,et al.  Parkin Increases Dopamine Uptake by Enhancing the Cell Surface Expression of Dopamine Transporter* , 2004, Journal of Biological Chemistry.

[108]  A. Singleton,et al.  A common genetic factor for Parkinson disease in ethnic Chinese population in Taiwan , 2006, BMC neurology.

[109]  Harry T Orr,et al.  Trinucleotide repeat disorders. , 2007, Annual review of neuroscience.

[110]  N. Hattori,et al.  Parkin stabilizes PINK1 through direct interaction. , 2009, Biochemical and biophysical research communications.

[111]  R. P. Maguire,et al.  Familial parkinsonism with synuclein pathology: Clinical and PET studies of A30P mutation carriers , 2001 .

[112]  J. Hardy,et al.  The genetics of Parkinson's syndromes: a critical review. , 2009, Current opinion in genetics & development.

[113]  David W. Miller,et al.  Mitochondrial Alterations in PINK1 Deficient Cells Are Influenced by Calcineurin-Dependent Dephosphorylation of Dynamin-Related Protein 1 , 2009, PloS one.

[114]  J. Vicencio,et al.  Ca2+, autophagy and protein degradation: thrown off balance in neurodegenerative disease. , 2010, Cell calcium.

[115]  R. Marconi,et al.  Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease , 2006, European Journal of Human Genetics.

[116]  E. Friedman,et al.  The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation , 2009, Journal of Neurology.

[117]  P. Deyn,et al.  GIGYF2 has no major role in Parkinson genetic etiology in a Belgian population , 2011, Neurobiology of Aging.

[118]  Y. Agid,et al.  A multidisciplinary study of patients with early-onset PD with and without parkin mutations , 2009, Neurology.

[119]  R. Barker,et al.  A case of late onset sporadic Parkinson’s disease with an A53T mutation in α-synuclein , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[120]  D. Sulzer,et al.  Proteasomal inhibition leads to formation of ubiquitin/α‐synuclein‐immunoreactive inclusions in PC12 cells , 2001, Journal of neurochemistry.

[121]  R. Barbour,et al.  Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease* , 2006, Journal of Biological Chemistry.

[122]  Alexandra Durr,et al.  How much phenotypic variation can be attributed to parkin genotype? , 2003, Annals of neurology.

[123]  Yuliang Wu,et al.  Direct binding of α‐actinin enhances TRPP3 channel activity , 2007 .

[124]  S. Lindquist,et al.  Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. , 2003, Science.

[125]  G. Zeevalk,et al.  Glutathione and Parkinson's disease: is this the elephant in the room? , 2008, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[126]  David F. Clayton,et al.  Characterization of a novel protein regulated during the critical period for song learning in the zebra finch , 1995, Neuron.

[127]  E. Masliah,et al.  α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.

[128]  P. Heutink,et al.  Loss of function of DJ-1 triggered by Parkinson's disease-associated mutation is due to proteolytic resistance to caspase-6 , 2010, Cell Death and Differentiation.

[129]  Matthew J. Farrer,et al.  LRRK2 in Parkinson's disease: protein domains and functional insights , 2006, Trends in Neurosciences.

[130]  D W Dickson,et al.  Autosomal dominant parkinsonism associated with variable synuclein and tau pathology , 2004, Neurology.

[131]  T. Niki,et al.  DJ‐1 has a role in antioxidative stress to prevent cell death , 2004, EMBO reports.

[132]  Mohamad Saad,et al.  Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies , 2011, The Lancet.

[133]  A. Whitworth,et al.  Drosophila Parkin requires PINK1 for mitochondrial translocation and ubiquitinates Mitofusin , 2010, Proceedings of the National Academy of Sciences.

[134]  A. Bentivoglio,et al.  Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. , 2001, American journal of human genetics.

[135]  D. Turnbull,et al.  MITOCHONDRIAL FUNCTION IN PARKINSON'S DISEASE , 1989, The Lancet.

[136]  R. S. Burns,et al.  Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism , 1984, Nature.

[137]  M. Iwata,et al.  Parkin-positive autosomal recessive juvenile parkinsonism with α-synuclein-positive inclusions , 2004, Neurology.

[138]  P. Blain,et al.  Mitochondrial Dysfunction in Parkinson's Disease , 2011, Parkinson's disease.

[139]  A. Lees,et al.  Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress , 2006, Journal of neurochemistry.

[140]  S. Yazawa,et al.  Familial Parkinsonism with digenic parkin and PINK1 mutations , 2008, Movement disorders : official journal of the Movement Disorder Society.

[141]  C. Ross,et al.  Parkin Mediates Nonclassical, Proteasomal-Independent Ubiquitination of Synphilin-1: Implications for Lewy Body Formation , 2005, The Journal of Neuroscience.

[142]  H Okazaki,et al.  Hereditary form of parkinsonism—dementia , 1998, Annals of neurology.

[143]  J. Cooper,et al.  Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons , 2006, Annals of neurology.

[144]  A. Dahlström,et al.  Differential localization of alpha-, beta- and gamma-synucleins in the rat CNS. , 2002, Neuroscience.

[145]  I. König,et al.  Co-occurrence of affective and schizophrenia spectrum disorders with PINK1 mutations , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[146]  C. Ki,et al.  The Ala53Thr mutation in the α‐synuclein gene in a Korean family with Parkinson disease , 2007 .

[147]  Fabienne C. Fiesel,et al.  PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1 , 2010, Nature Cell Biology.

[148]  J. Trojanowski,et al.  Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.

[149]  Y. Yoon,et al.  Perturbations in Mitochondrial Dynamics Induced by Human Mutant PINK1 Can Be Rescued by the Mitochondrial Division Inhibitor mdivi-1* , 2010, The Journal of Biological Chemistry.

[150]  T. Hashikawa,et al.  CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity. , 2002, Molecular cell.

[151]  Roya Saffary,et al.  Inclusion Body Formation and Neurodegeneration Are Parkin Independent in a Mouse Model of α-Synucleinopathy , 2006, The Journal of Neuroscience.

[152]  Yih-Ru Wu,et al.  Lrrk2 R1628P in non‐Chinese Asian races , 2008, Annals of neurology.

[153]  C. Culmsee,et al.  Parkin Mediates Neuroprotection through Activation of IκB Kinase/Nuclear Factor-κB Signaling , 2007, The Journal of Neuroscience.

[154]  David W. Miller,et al.  Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[155]  Y. Mizuno,et al.  Clinical, pathologic and genetic studies on autosomal recessive early-onset parkinsonism with diurnal fluctuation. , 1998, Parkinsonism & related disorders.

[156]  J Q Trojanowski,et al.  Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. , 1998, The American journal of pathology.

[157]  A. Brice,et al.  A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K–Akt signalling , 2006, Nature Cell Biology.

[158]  J. Menéndez,et al.  Midbrain neuronal cultures from parkin mutant mice are resistant to nitric oxide-induced toxicity , 2006, Neuropharmacology.

[159]  J. Jankovic,et al.  GIGYF2 Asn56Ser and Asn457Thr mutations in Parkinson disease patients , 2009, Neuroscience Letters.

[160]  R. Pfeiffer,et al.  A Greek‐American kindred with autosomal dominant, levodopa‐responsive parkinsonism and anticipation , 1995, Annals of neurology.

[161]  J. Nutt,et al.  Genetic association between α‐synuclein and idiopathic parkinson's disease , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[162]  M. Farrer,et al.  Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson’s disease , 1999, Neurology.

[163]  K. Marder,et al.  Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations , 2009, Neurology.

[164]  V. Bader,et al.  Mono- and double-mutant mouse models of Parkinson's disease display severe mitochondrial damage. , 2007, Human molecular genetics.

[165]  G. Hadjigeorgiou,et al.  Mutated alpha-synuclein gene in two Greek kindreds with familial PD: incomplete penetrance? , 1999, Neurology.

[166]  M. Farrer,et al.  Reported mutations in GIGYF2 are not a common cause of Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[167]  N. Hattori,et al.  Parkin Cleaves Intracellular α-Synuclein Inclusions via the Activation of Calpain* , 2003, Journal of Biological Chemistry.

[168]  J. Trojanowski,et al.  Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. , 2003, Biochemistry.

[169]  Stéphane Thobois,et al.  Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa. , 2006, Brain : a journal of neurology.

[170]  Wenbo Zhou,et al.  DJ-1 Up-regulates Glutathione Synthesis during Oxidative Stress and Inhibits A53T α-Synuclein Toxicity* , 2005, Journal of Biological Chemistry.

[171]  A. Dahlström,et al.  Differential localization of α-, β- and γ-synucleins in the rat CNS , 2002, Neuroscience.

[172]  A. Whitworth,et al.  Drosophila HtrA2 is dispensable for apoptosis but acts downstream of PINK1 independently from Parkin , 2009, Cell Death and Differentiation.

[173]  G. Seidel,et al.  Substantia nigra hyperechogenicity correlates with clinical status and number of Parkin mutated alleles , 2007, Journal of Neurology.

[174]  R. Baggott DISEASE , 1947, Social Policy & Administration.

[175]  D. Selkoe,et al.  Dopamine covalently modifies and functionally inactivates parkin , 2005, Nature Medicine.

[176]  J. Trojanowski,et al.  Biochemical and pathological characterization of Lrrk2 , 2006, Annals of neurology.

[177]  Gwang Lee,et al.  Molecular interaction between parkin and PINK1 in mammalian neuronal cells , 2009, Molecular and Cellular Neuroscience.

[178]  J. Haines,et al.  Parkin mutations and susceptibility alleles in late‐onset Parkinson's disease , 2003, Annals of neurology.

[179]  J. C. Greene,et al.  Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[180]  N. Bonini,et al.  DJ‐1 is present in a large molecular complex in human brain tissue and interacts with α‐synuclein , 2005, Journal of neurochemistry.

[181]  B. Hyman,et al.  Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. , 2002, The American journal of pathology.

[182]  B. E. Staveley,et al.  Pink1 suppresses alpha-synuclein-induced phenotypes in a Drosophila model of Parkinson's disease. , 2008, Genome.

[183]  M. Farrer,et al.  Parkin variants in North American Parkinson's disease: Cases and controls , 2003, Movement disorders : official journal of the Movement Disorder Society.

[184]  M. Farrer,et al.  Clinical characteristics of Parkinson’s disease among Jewish Ethnic groups in Israel , 2008, Journal of Neural Transmission.

[185]  T. Foroud,et al.  Mutations in DJ-1 are rare in familial Parkinson disease , 2006, Neuroscience Letters.

[186]  J. Trojanowski,et al.  Phosphorylated α-Synuclein Is Ubiquitinated in α-Synucleinopathy Lesions* , 2002, The Journal of Biological Chemistry.

[187]  A. Schapira Future directions in the treatment of Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[188]  C. Duyckaerts,et al.  Leucine-Rich Repeat Kinase 2 Is Associated With the Endoplasmic Reticulum in Dopaminergic Neurons and Accumulates in the Core of Lewy Bodies in Parkinson Disease , 2010, Journal of neuropathology and experimental neurology.

[189]  Ren-Shyan Liu,et al.  Presence of spinocerebellar ataxia type 2 gene mutation in a patient with apparently sporadic Parkinson's disease: Clinical implications , 2004, Movement disorders : official journal of the Movement Disorder Society.

[190]  K. Lohmann,et al.  Genetic association study of the P‐type ATPase ATP13A2 in late‐onset Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[191]  A. Singleton,et al.  Screening for LRRK2 mutations in patients with Parkinson’s disease in Russia: identification of a novel LRRK2 variant , 2008, European journal of neurology.

[192]  N. Hattori,et al.  An Unfolded Putative Transmembrane Polypeptide, which Can Lead to Endoplasmic Reticulum Stress, Is a Substrate of Parkin , 2001, Cell.

[193]  H. Shill,et al.  The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study , 2008, BMC medicine.

[194]  J. Growdon,et al.  A haplotype at the PARK3 locus influences onset age for Parkinson’s disease , 2003, Neurology.

[195]  E. Hirsch,et al.  Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. , 2003, Human molecular genetics.

[196]  Erika K Wallender,et al.  Optical Reporters for the Conformation of α-Synuclein Reveal a Specific Interaction with Mitochondria , 2008, The Journal of Neuroscience.

[197]  C. Olanow,et al.  Leucine‐rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson’s disease R1441C/G mutants , 2007, Journal of neurochemistry.

[198]  John Q. Trojanowski,et al.  Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease , 2001, Science.

[199]  R. Krüger,et al.  Reduced Basal Autophagy and Impaired Mitochondrial Dynamics Due to Loss of Parkinson's Disease-Associated Protein DJ-1 , 2010, PloS one.

[200]  David S. Park,et al.  Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP , 2008, Proceedings of the National Academy of Sciences.

[201]  P. Pollak,et al.  Parkinson's disease-related LRRK2 G2019S mutation results from independent mutational events in humans. , 2010, Human molecular genetics.

[202]  T. Foroud,et al.  Variation in GIGYF2 is not associated with Parkinson disease , 2009, Neurology.

[203]  E. Masliah,et al.  alpha-Synuclein is phosphorylated in synucleinopathy lesions. , 2002, Nature cell biology.

[204]  R. Krüger,et al.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.

[205]  M. Cookson,et al.  The Parkinson Disease-associated Leucine-rich Repeat Kinase 2 (LRRK2) Is a Dimer That Undergoes Intramolecular Autophosphorylation* , 2008, Journal of Biological Chemistry.

[206]  C. Duyckaerts,et al.  Parkin Deficiency Delays Motor Decline and Disease Manifestation in a Mouse Model of Synucleinopathy , 2009, PloS one.

[207]  Bryan L Roth,et al.  Parkin-deficient Mice Exhibit Nigrostriatal Deficits but Not Loss of Dopaminergic Neurons* , 2003, Journal of Biological Chemistry.

[208]  F. Binkofski,et al.  ATP13A2 variants in early‐onset Parkinson's disease patients and controls , 2009, Movement disorders : official journal of the Movement Disorder Society.

[209]  O. Bandmann,et al.  p53‐dependent neuronal cell death in a DJ‐1‐deficient zebrafish model of Parkinson's disease , 2006, Journal of neurochemistry.

[210]  P. Axelsen,et al.  Role of α-Synuclein Carboxy-Terminus on Fibril Formation in Vitro† , 2003 .

[211]  J. Kordower,et al.  Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys , 2006, Annals of neurology.

[212]  J. Rothwell,et al.  Motor cortical physiology in patients and asymptomatic carriers of parkin gene mutations , 2008, Movement disorders : official journal of the Movement Disorder Society.

[213]  Peter K. Kim,et al.  Mitochondria Supply Membranes for Autophagosome Biogenesis during Starvation , 2010, Cell.

[214]  W. Oyen,et al.  FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome , 2009, Neurology.

[215]  Leonidas Stefanis,et al.  Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. , 2004, Science.

[216]  Hansong Deng,et al.  The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila , 2008, Proceedings of the National Academy of Sciences.

[217]  A. Singleton,et al.  Parkinson's disease due to the R1441G mutation in Dardarin: A founder effect in the basques , 2006, Movement disorders : official journal of the Movement Disorder Society.

[218]  C. Lautier,et al.  Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. , 2008, American journal of human genetics.

[219]  S. Lindquist,et al.  α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models , 2006, Science.

[220]  Penny A. MacDonald,et al.  Parkin-mediated monoubiquitination of the PDZ protein PICK1 regulates the activity of acid-sensing ion channels. , 2007, Molecular biology of the cell.

[221]  Asunción Delgado,et al.  Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation. , 2007, Human molecular genetics.

[222]  Patrick M. Abou-Sleiman,et al.  Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease , 2009, Nature Cell Biology.

[223]  A. Singleton,et al.  G2019S dardarin substitution is a common cause of Parkinson's disease in a Portuguese cohort , 2005, Movement disorders : official journal of the Movement Disorder Society.

[224]  C. Ross,et al.  Parkin ubiquitinates the α-synuclein–interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease , 2001, Nature Medicine.

[225]  M. Augustin,et al.  Parkin expression in the adult mouse brain , 2000, The European journal of neuroscience.

[226]  A. Mosley,et al.  A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations , 2005, Neurology.

[227]  Michael R. Duchen,et al.  PINK1-Associated Parkinson's Disease Is Caused by Neuronal Vulnerability to Calcium-Induced Cell Death , 2009, Molecular cell.

[228]  H. Cai,et al.  Leucine-Rich Repeat Kinase 2 Regulates the Progression of Neuropathology Induced by Parkinson's-Disease-Related Mutant α-synuclein , 2009, Neuron.

[229]  P. Remy,et al.  Chronic systemic treatment with a high-dose proteasome inhibitor in mice produces akinesia unrelated to nigrostriatal degeneration , 2011, Neurobiology of Aging.

[230]  M. Spillantini,et al.  α‐Synuclein metabolism and aggregation is linked to ubiquitin‐independent degradation by the proteasome , 2001, FEBS letters.

[231]  R. Nussbaum,et al.  Parkinson Phenotype in Aged PINK1-Deficient Mice Is Accompanied by Progressive Mitochondrial Dysfunction in Absence of Neurodegeneration , 2009, PloS one.

[232]  P. S. St George-Hyslop,et al.  Wild-type PINK1 Prevents Basal and Induced Neuronal Apoptosis, a Protective Effect Abrogated by Parkinson Disease-related Mutations* , 2005, Journal of Biological Chemistry.

[233]  David S. Park,et al.  Loss of PINK1 Function Promotes Mitophagy through Effects on Oxidative Stress and Mitochondrial Fission* , 2009, Journal of Biological Chemistry.

[234]  M. Farrer,et al.  α‐Synuclein promoter confers susceptibility to Parkinson's disease , 2004 .

[235]  C. Marsden,et al.  A 31P magnetic resonance spectroscopy study of mitochondrial function in skeletal muscle of patients with Parkinson's disease , 1994, Journal of the Neurological Sciences.

[236]  William Lin,et al.  Characterization of PINK1 processing, stability, and subcellular localization , 2008, Journal of neurochemistry.

[237]  T. Mitsui,et al.  Parkin enhances mitochondrial biogenesis in proliferating cells. , 2006, Human molecular genetics.

[238]  J. Trojanowski,et al.  Concurrence of α-synuclein and tau brain pathology in the Contursi kindred , 2002, Acta Neuropathologica.

[239]  N. Avadhani,et al.  Mitochondrial Import and Accumulation of α-Synuclein Impair Complex I in Human Dopaminergic Neuronal Cultures and Parkinson Disease Brain* , 2008, Journal of Biological Chemistry.

[240]  Jian Feng,et al.  Parkin Protects Dopaminergic Neurons against Microtubule-depolymerizing Toxins by Attenuating Microtubule-associated Protein Kinase Activation* , 2009, Journal of Biological Chemistry.

[241]  Tatiana Foroud,et al.  Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease , 2005, The Lancet.

[242]  Matthew J. Farrer,et al.  α-synuclein gene haplotypes are associated with Parkinson’s disease , 2001 .

[243]  Ming Zhan,et al.  RNA binding activity of the recessive parkinsonism protein DJ-1 supports involvement in multiple cellular pathways , 2008, Proceedings of the National Academy of Sciences.

[244]  J. Ahlskog Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson's disease. , 2009, Parkinsonism & related disorders.

[245]  Y. Teo,et al.  Alpha-synuclein haplotypes implicated in risk of Parkinson’s disease , 2004, Neurology.

[246]  Marc Cruts,et al.  Genetic Etiology of Parkinson Disease Associated with Mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 Genes: A Mutation Update , 2010, Human mutation.

[247]  A. Pisani,et al.  Impaired dopamine release and synaptic plasticity in the striatum of Parkin−/− mice , 2009, Journal of neurochemistry.

[248]  G. Opala,et al.  Analysis of LRRK2 G2019S and I2020T mutations in Parkinson's disease , 2005, Neuroscience Letters.

[249]  P. Lansbury,et al.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[250]  J. Aharon-Peretz,et al.  Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. , 2004, The New England journal of medicine.

[251]  Christine Klein,et al.  LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. , 2006, The New England journal of medicine.

[252]  Eden R Martin,et al.  Genome-wide linkage screen in familial Parkinson disease identifies loci on chromosomes 3 and 18. , 2009, American journal of human genetics.

[253]  V. Emmel,et al.  Intrafamilial variability of Parkinson phenotype in SCAs: novel cases due to SCA2 and SCA3 expansions. , 2009, Parkinsonism & related disorders.

[254]  Shu G. Chen,et al.  The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. , 2007, Experimental cell research.

[255]  Nobutaka Hattori,et al.  The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson's disease. , 2005, Parkinsonism & related disorders.

[256]  H. McBride Parkin mitochondria in the autophagosome , 2008, The Journal of cell biology.

[257]  P. Kolatkar,et al.  The LRRK2 Gly2385Arg variant is associated with Parkinson’s disease: genetic and functional evidence , 2006, Human Genetics.

[258]  P. Lansbury,et al.  The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states. , 2007, Biochemistry.

[259]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[260]  A. Bentivoglio,et al.  PINK1 mutations are associated with sporadic early‐onset parkinsonism , 2004, Annals of neurology.

[261]  R. Nussbaum,et al.  Mitochondrial translocation of alpha-synuclein is promoted by intracellular acidification. , 2008, Experimental cell research.

[262]  P. V. van Haastert,et al.  Roc, a Ras/GTPase domain in complex proteins. , 2003, Biochimica et biophysica acta.

[263]  F. Checler,et al.  Alpha-synuclein lowers p53-dependent apoptotic response of neuronal cells. Abolishment by 6-hydroxydopamine and implication for Parkinson's disease. , 2002, The Journal of biological chemistry.

[264]  Atsushi Tanaka,et al.  PINK1 Is Selectively Stabilized on Impaired Mitochondria to Activate Parkin , 2010, PLoS biology.

[265]  P. Pollak,et al.  Multifocal enhancing cortical lesions in a patient with Churg-Strauss syndrome , 2008, Neurology.

[266]  Z. Wszolek,et al.  Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. , 2009, Parkinsonism & related disorders.

[267]  M. Farrer,et al.  Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. , 2004, Annals of neurology.

[268]  J. Trojanowski,et al.  Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. , 2002, The Journal of biological chemistry.

[269]  J. Trojanowski,et al.  Parkinson's disease and related synucleinopathies are a new class of nervous system amyloidoses. , 2002, Neurotoxicology.

[270]  T. Katada,et al.  GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. , 2007, Biochemistry.

[271]  E. Tan,et al.  Molecular biology changes associated with LRRK2 mutations in Parkinson's disease , 2008, Journal of neuroscience research.

[272]  B. Giasson,et al.  DJ-1 deficient mice demonstrate similar vulnerability to pathogenic Ala53Thr human alpha-syn toxicity. , 2010, Human molecular genetics.

[273]  M. Farrer,et al.  Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease , 2008, Annals of neurology.

[274]  Bertram Müller-Myhsok,et al.  The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. , 2004, American journal of human genetics.

[275]  Matthew J. Farrer,et al.  Digenic parkinsonism: Investigation of the synergistic effects of PRKN and LRRK2 , 2006, Neuroscience Letters.

[276]  G. Schellenberg,et al.  LRRK2 mutations and risk variants in Japanese patients with Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[277]  P. Lansbury,et al.  Membrane-associated farnesylated UCH-L1 promotes α-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease , 2009, Proceedings of the National Academy of Sciences.

[278]  R. Youle,et al.  Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL , 2010, The Journal of cell biology.

[279]  A. Bonnet,et al.  A-SYNUCLEIN GENE DUPLICATION IS PRESENT IN SPORADIC PARKINSON DISEASE. Authors' reply , 2008 .

[280]  R. Marconi,et al.  GIGYF2 mutations are not a frequent cause of familial Parkinson's disease. , 2009, Parkinsonism & related disorders.

[281]  D. Eliezer,et al.  Effects of Parkinson's disease-linked mutations on the structure of lipid-associated α-Synuclein , 2004 .

[282]  K. Moore,et al.  Induction of the Phase II Detoxification Pathway Suppresses Neuron Loss in Drosophila Models of Parkinson's Disease , 2008, The Journal of Neuroscience.

[283]  E. Sidransky,et al.  Glucocerebrosidase mutations in subjects with parkinsonism. , 2004, Molecular genetics and metabolism.

[284]  C. Olanow,et al.  Selective loss of 20S proteasome α-subunits in the substantia nigra pars compacta in Parkinson's disease , 2002, Neuroscience Letters.

[285]  G. Schellenberg,et al.  Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. , 2008, Archives of neurology.

[286]  S. Kuno,et al.  Cytoplasmic transfer of platelet mtDNA from elderly patients with Parkinson's disease to mtDNA-less HeLa cells restores complete mitochondrial respiratory function. , 2001, Biochemical and biophysical research communications.

[287]  K. Marder,et al.  Frequency of parkin mutations in late‐onset Parkinson's disease , 2003, Annals of neurology.

[288]  A. Landau,et al.  Proteasome inhibitor model of Parkinson's disease in mice is confounded by neurotoxicity of the ethanol vehicle , 2007, Movement disorders : official journal of the Movement Disorder Society.

[289]  Robert Hill,et al.  Low platelet mitochondrial complex I and complex II/III activity in early untreated parkinson's disease , 1995, Annals of neurology.

[290]  S E Ide,et al.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.

[291]  M. Farrer,et al.  Glucosidase-beta variations and Lewy body disorders. , 2009, Parkinsonism & related disorders.

[292]  M. Cookson,et al.  Genetic neuropathology of Parkinson's disease. , 2008, International journal of clinical and experimental pathology.

[293]  Biao Chen,et al.  ACT and UCH‐L1 polymorphisms in Parkinson's disease and age of onset , 2002, Movement disorders : official journal of the Movement Disorder Society.

[294]  E. Masliah,et al.  alpha-Synuclein aggregates interfere with Parkin solubility and distribution: role in the pathogenesis of Parkinson disease. , 2008, The Journal of biological chemistry.

[295]  K. Doheny,et al.  Genomewide association study for susceptibility genes contributing to familial Parkinson disease , 2009, Human Genetics.

[296]  C. Marsden,et al.  Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. , 1992, Brain : a journal of neurology.

[297]  Li Zhang,et al.  A missense mutation (L166P) in DJ‐1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo‐oligomerization , 2003, Journal of neurochemistry.

[298]  S. Choudhry,et al.  CAG repeat instability at SCA2 locus: anchoring CAA interruptions and linked single nucleotide polymorphisms. , 2001, Human molecular genetics.

[299]  Glenda M. Halliday,et al.  Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr α‐synuclein mutation , 2001 .

[300]  P. McPherson,et al.  SH3 domains from a subset of BAR proteins define a Ubl-binding domain and implicate parkin in synaptic ubiquitination. , 2009, Molecular cell.

[301]  A. Brice,et al.  Of Parkin and Parkinson's: light and dark sides of a multifaceted E3 ubiquitin–protein ligase , 2007 .

[302]  P. Aebischer,et al.  α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[303]  M. Cookson,et al.  Leucine-rich repeat kinase 2 mutations and Parkinson’s disease: three questions , 2009, ASN neuro.

[304]  M. Cookson,et al.  Parkinson's disease: insights from pathways. , 2010, Human molecular genetics.

[305]  Jeremy N. Skepper,et al.  α-Synuclein Is Degraded by Both Autophagy and the Proteasome* , 2003, Journal of Biological Chemistry.

[306]  R. Mandel,et al.  The phosphorylation state of Ser-129 in human α-synuclein determines neurodegeneration in a rat model of Parkinson disease , 2008, Proceedings of the National Academy of Sciences.

[307]  Bonifati,et al.  Association between early-onset Parkinson's disease and mutations in the parkin gene. , 2000, The New England journal of medicine.

[308]  Matthew J. Farrer,et al.  Comparison of kindreds with parkinsonism and α‐synuclein genomic multiplications , 2004 .

[309]  P. Amouyel,et al.  S18Y polymorphism in the UCH‐L1 gene and Parkinson's disease: Evidence for an age‐dependent relationship , 2003, Movement disorders : official journal of the Movement Disorder Society.

[310]  D. Berg,et al.  Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair. , 2009, Human molecular genetics.

[311]  Jin Man Kim,et al.  Parkin negatively regulates JNK pathway in the dopaminergic neurons of Drosophila. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[312]  M. Farrer,et al.  PARK11 is not linked with Parkinson's disease in European families , 2005, European Journal of Human Genetics.

[313]  Christian Haass,et al.  Structure/function of alpha-synuclein in health and disease: rational development of animal models for Parkinson's and related diseases. , 2002, Journal of neurochemistry.

[314]  L. Chin,et al.  Ubiquitination of alpha-synuclein by Siah-1 promotes alpha-synuclein aggregation and apoptotic cell death. , 2008, Human molecular genetics.

[315]  L. Meijer,et al.  Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. , 2000, The Journal of biological chemistry.

[316]  R. Krüger,et al.  Haploinsufficiency at the α‐synuclein gene underlies phenotypic severity in familial Parkinson’s disease , 2003 .

[317]  J. Parks,et al.  Abnormalities of the electron transport chain in idiopathic parkinson's disease , 1989, Annals of neurology.

[318]  M. Feany,et al.  α-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease , 2005, Nature Neuroscience.

[319]  Yi Zhao,et al.  Case–control study of UCHL1 S18Y variant in Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[320]  M. Farrer,et al.  Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. , 2006, Archives of neurology.

[321]  K. Xia,et al.  Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease. , 2006, Human molecular genetics.

[322]  A. Kakita,et al.  Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia. , 2008, Archives of neurology.

[323]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[324]  E. Masliah,et al.  β-Synuclein Displays an Antiapoptotic p53-dependent Phenotype and Protects Neurons from 6-Hydroxydopamine-induced Caspase 3 Activation , 2003, Journal of Biological Chemistry.

[325]  A. Lees,et al.  Kufor Rakeb Disease: Autosomal recessive, levodopa‐responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia , 2005, Movement disorders : official journal of the Movement Disorder Society.

[326]  Robert W. Taylor,et al.  High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease , 2006, Nature Genetics.

[327]  P. Pollak,et al.  Progressive encephalomyelitis with rigidity and myoclonus: Resolution after thymectomy , 2011, Neurology.

[328]  A. López de Munain,et al.  LRRK2 G2019S and R1441G mutations associated with Parkinson’s disease are common in the Basque Country, but relative prevalence is determined by ethnicity , 2009, neurogenetics.

[329]  R. King,et al.  Differential effects of PINK1 nonsense and missense mutations on mitochondrial function and morphology , 2009, Experimental Neurology.

[330]  H. Payami,et al.  Escaping Parkinson's disease: A neurologically healthy octogenarian with the LRRK2 G2019S mutation , 2005, Movement disorders : official journal of the Movement Disorder Society.

[331]  J. Kaye,et al.  Genetic anticipation in Parkinson's disease , 1995, Neurology.

[332]  T. Foroud,et al.  LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8 , 2007, Neurology.

[333]  A. Singleton,et al.  Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. , 2009, Brain : a journal of neurology.

[334]  E. Tolosa,et al.  G2019S LRRK2 mutation causing Parkinson’s disease without Lewy bodies , 2007, Journal of Neurology, Neurosurgery & Psychiatry.

[335]  M. Beal,et al.  Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[336]  S. Lincoln,et al.  UCHL1 is associated with Parkinson's disease: A case-unaffected sibling and case-unrelated control study , 2005, Neuroscience Letters.

[337]  C. Southan,et al.  Characterization of human HtrA2, a novel serine protease involved in the mammalian cellular stress response. , 2000, European journal of biochemistry.

[338]  J. Haines,et al.  A Genome‐wide Scan in an Amish Pedigree with Parkinsonism , 2008, Annals of human genetics.

[339]  C. Tai,et al.  Non-synonymous GIGYF2 variants in Parkinson’s disease from two Asian populations , 2009, Human Genetics.

[340]  L. Chin,et al.  Phosphorylation of parkin by Parkinson disease-linked kinase PINK1 activates parkin E3 ligase function and NF-kappaB signaling. , 2010, Human molecular genetics.

[341]  Hitoshi Takahashi,et al.  An autopsy case of autosomal‐recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene , 2000, Movement disorders : official journal of the Movement Disorder Society.

[342]  Vincenzo Bonifati,et al.  A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease , 2005, The Lancet.

[343]  T. Dawson,et al.  Identification of Far Upstream Element-binding Protein-1 as an Authentic Parkin Substrate* , 2006, Journal of Biological Chemistry.

[344]  Jan Gründemann,et al.  Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase , 2006, Nature Genetics.

[345]  D. Maraganore,et al.  UCHL1 is a Parkinson's disease susceptibility gene , 2004, Annals of neurology.

[346]  S. Tabrizi,et al.  Correction: PINK1 Is Necessary for Long Term Survival and Mitochondrial Function in Human Dopaminergic Neurons , 2008, PLoS ONE.

[347]  Philippe Amouyel,et al.  α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.

[348]  R. Nichols,et al.  LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. , 2007, The Biochemical journal.

[349]  D. Godin,et al.  Parkinson's disease: A disorder due to nigral glutathione deficiency? , 1982, Neuroscience Letters.

[350]  C. Gerloff,et al.  Sensorimotor integration is abnormal in asymptomatic Parkin mutation carriers , 2007, Neurology.

[351]  A. Felício,et al.  PINK1 mutations in a Brazilian cohort of early‐onset Parkinson's disease patients , 2009, Movement disorders : official journal of the Movement Disorder Society.

[352]  A. Brice,et al.  A new complex homozygous large rearrangement of the PINK1 gene in a Sudanese family with early onset Parkinson’s disease , 2009, neurogenetics.

[353]  C. Warren Olanow,et al.  Altered Proteasomal Function in Sporadic Parkinson's Disease , 2003, Experimental Neurology.

[354]  B. Jeon,et al.  α-Synuclein gene duplication is present in sporadic Parkinson disease , 2008, Neurology.

[355]  D. Sulzer,et al.  Interplay between Cytosolic Dopamine, Calcium, and α-Synuclein Causes Selective Death of Substantia Nigra Neurons , 2009, Neuron.

[356]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[357]  Shinsei Minoshima,et al.  Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase , 2000, Nature Genetics.

[358]  B. Hyman,et al.  Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. , 2004, The Journal of biological chemistry.

[359]  R. Scheller,et al.  Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[360]  E. Tan,et al.  Novel ATP13A2 variant associated with Parkinson disease in Taiwan and Singapore , 2008, Neurology.

[361]  G. Dorn,et al.  Nix Is Critical to Two Distinct Phases of Mitophagy, Reactive Oxygen Species-mediated Autophagy Induction and Parkin-Ubiquitin-p62-mediated Mitochondrial Priming* , 2010, The Journal of Biological Chemistry.

[362]  S. Murayama,et al.  [Autopsy case of SCA2 with Parkinsonian phenotype]. , 2010, Rinsho shinkeigaku = Clinical neurology.

[363]  M. Farrer,et al.  Analysis of LRRK2 functional domains in nondominant Parkinson disease , 2005, Neurology.

[364]  Kostas Vekrellis,et al.  Wild Type α-Synuclein Is Degraded by Chaperone-mediated Autophagy and Macroautophagy in Neuronal Cells* , 2008, Journal of Biological Chemistry.

[365]  Richard Paylor,et al.  Synaptic Vesicle Depletion Correlates with Attenuated Synaptic Responses to Prolonged Repetitive Stimulation in Mice Lacking α-Synuclein , 2002, The Journal of Neuroscience.

[366]  B. Jeon,et al.  The G2019S LRRK2 Mutation is Rare in Korean Patients with Parkinson's Disease and Multiple System Atrophy , 2009, Journal of clinical neurology.

[367]  K. Marder,et al.  Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease , 2007, Neurology.

[368]  J. Langston,et al.  Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. , 2009, Neurotoxicology.

[369]  R. Swerdlow,et al.  Origin and functional consequences of the complex I defect in Parkinson's disease , 1996, Annals of neurology.

[370]  J. Trojanowski,et al.  Induction of alpha-synuclein aggregation by intracellular nitrative insult. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[371]  A. Dürr,et al.  Rare heterozygous parkin variants in French early-onset Parkinson disease patients and controls , 2007, Journal of Medical Genetics.

[372]  T. Foroud,et al.  Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset , 2009, Neurology.

[373]  Kazuko Hasegawa,et al.  An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family , 2005, Annals of neurology.

[374]  C. Ross,et al.  Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[375]  Armin Giese,et al.  Inhibition of mitochondrial fusion by α‐synuclein is rescued by PINK1, Parkin and DJ‐1 , 2010, The EMBO journal.

[376]  Joachim Klose,et al.  Mitochondrial Dysfunction and Oxidative Damage in parkin-deficient Mice* , 2004, Journal of Biological Chemistry.

[377]  Richard Wade-Martins,et al.  LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. , 2009, Human molecular genetics.

[378]  P. S. St George-Hyslop,et al.  Analysis of the glucocerebrosidase gene in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[379]  S. Bardien,et al.  Analysis of exon dosage using MLPA in South African Parkinson's disease patients , 2010, neurogenetics.

[380]  D. Sulzer,et al.  Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. , 2000, Neuron.

[381]  E. Sidransky Gaucher disease: complexity in a "simple" disorder. , 2004, Molecular genetics and metabolism.

[382]  R. Edwards,et al.  Lipid rafts mediate the synaptic localization of alpha-synuclein. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[383]  Mathias Toft,et al.  MAPK‐pathway activity, Lrrk2 G2019S, and Parkinson's disease , 2007, Journal of neuroscience research.

[384]  C A Ross,et al.  Synphilin‐1 is present in Lewy bodies in Parkinson's disease , 2000, Annals of neurology.

[385]  C. Klein,et al.  Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway. , 2010, Cellular signalling.

[386]  G. Schellenberg,et al.  Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients , 2007, Annals of neurology.

[387]  J. Johnson,et al.  Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variants , 2007, European journal of neurology.

[388]  A. Sprenger,et al.  Transcranial sonography findings in a large family with homozygous and heterozygous PINK1 mutations , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[389]  A. Elbaz,et al.  Update in the epidemiology of Parkinson's disease , 2008, Current opinion in neurology.

[390]  Robert Edwards,et al.  Lipid Rafts Mediate the Synaptic Localization of α-Synuclein , 2004, The Journal of Neuroscience.

[391]  D. James Surmeier,et al.  ‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease , 2007, Nature.

[392]  J. Burgunder,et al.  ATP13A2 G2236A variant is rare in patients with early-onset Parkinson's disease and familial Parkinson's disease from Mainland China. , 2010, Parkinsonism & related disorders.

[393]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[394]  Jochen Klucken,et al.  Hsp70 Reduces α-Synuclein Aggregation and Toxicity* , 2004, Journal of Biological Chemistry.

[395]  A. Matouschek,et al.  Aggregated and Monomeric α-Synuclein Bind to the S6′ Proteasomal Protein and Inhibit Proteasomal Function* , 2003, The Journal of Biological Chemistry.

[396]  P. Ragonese,et al.  Identification of the novel D297fsX318 PINK1 mutation and phenotype variation in a family with early-onset Parkinson's disease. , 2008, Parkinsonism & related disorders.

[397]  D. Hernandez,et al.  Analysis of SCA-2 and SCA-3 repeats in Parkinsonism: Evidence of SCA-2 expansion in a family with autosomal dominant Parkinson's disease , 2005, Neuroscience Letters.

[398]  M. Cookson,et al.  Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein. , 2009, The American journal of pathology.

[399]  A. Destée,et al.  Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. , 2009, Archives of neurology.

[400]  D. Hernandez,et al.  Characterization of PLA2G6 as a locus for dystonia‐parkinsonism , 2008, Annals of neurology.

[401]  J. Noth,et al.  DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease , 2004, Neurology.

[402]  C. Sampaio,et al.  High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal , 2007, Movement disorders : official journal of the Movement Disorder Society.

[403]  Mark A. Wilson,et al.  The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[404]  Y. Sohn,et al.  Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease , 2008, Neurogenetics.

[405]  M. Russo,et al.  The Parkinson-associated protein PINK1 interacts with Beclin1 and promotes autophagy , 2010, Cell Death and Differentiation.

[406]  Marc Liesa,et al.  Mitochondrial dynamics in mammalian health and disease. , 2009, Physiological reviews.

[407]  C. Ross,et al.  Kinase activity of mutant LRRK2 mediates neuronal toxicity , 2006, Nature Neuroscience.

[408]  T. Dawson,et al.  DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase , 2007, Proceedings of the National Academy of Sciences.

[409]  B. E. Staveley,et al.  Mutant α-synuclein-induced degeneration is reduced by parkin in a fly model of Parkinson's disease , 2006 .

[410]  David S. Park,et al.  Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics. , 2010, Human molecular genetics.

[411]  D. Price,et al.  Stabilization of α-Synuclein Protein with Aging and Familial Parkinson's Disease-Linked A53T Mutation , 2004, The Journal of Neuroscience.

[412]  YongSung Kim,et al.  PINK1 controls mitochondrial localization of Parkin through direct phosphorylation. , 2008, Biochemical and biophysical research communications.

[413]  E. Waxman,et al.  Specificity and Regulation of Casein Kinase-Mediated Phosphorylation of &agr;-Synuclein , 2008, Journal of neuropathology and experimental neurology.

[414]  A. Lang,et al.  The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. , 2001, Human molecular genetics.

[415]  M. Cookson,et al.  The R1441C mutation of LRRK2 disrupts GTP hydrolysis. , 2007, Biochemical and biophysical research communications.

[416]  A. Barzilai,et al.  The Involvement of p53 in Dopamine-Induced Apoptosis of Cerebellar Granule Neurons and Leukemic Cells Overexpressing p53 , 1999, Cellular and Molecular Neurobiology.

[417]  T. Nägele,et al.  Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. , 2005, Brain : a journal of neurology.

[418]  Homayoun Sadeghi,et al.  A clinic‐based screening of mutations in exons 31, 34, 35, 41, and 48 of LRRK2 in Iranian Parkinson's disease patients , 2009, Movement disorders : official journal of the Movement Disorder Society.

[419]  K. Marder,et al.  Association of glucocerebrosidase mutations with dementia with lewy bodies. , 2009, Archives of neurology.

[420]  P. Heutink,et al.  Genotypic and phenotypic characteristics of Dutch patients with early onset Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[421]  S. Paek,et al.  Spinocerebellar ataxia type 17 mutation as a causative and susceptibility gene in parkinsonism , 2009, Neurology.

[422]  Bruce A. Yankner,et al.  Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease , 2002, Nature Medicine.

[423]  E. Masliah,et al.  Beta-synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation: cross-talk with alpha-synuclein and implication for Parkinson's disease. , 2003, The Journal of biological chemistry.

[424]  C. van Broeckhoven,et al.  Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population , 2009, Human mutation.

[425]  T. Kondo,et al.  Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q , 1998, Neurology.

[426]  T. Nagatsu [Biochemistry of Parkinson's disease]. , 1988, Seikagaku. The Journal of Japanese Biochemical Society.

[427]  Donato A Di Monte,et al.  The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? , 2003, The Lancet Neurology.

[428]  J. Perlmutter,et al.  Association of α-synuclein gene haplotypes with Parkinson's disease , 2007 .

[429]  P. Verstreken,et al.  Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function , 2009, EMBO molecular medicine.

[430]  Vincenzo Bonifati,et al.  Early‐onset Parkinson's disease caused by a compound heterozygous DJ‐1 mutation , 2003, Annals of neurology.

[431]  N. Hattori,et al.  Diverse Effects of Pathogenic Mutations of Parkin That Catalyze Multiple Monoubiquitylation in Vitro* , 2006, Journal of Biological Chemistry.

[432]  R. Benecke,et al.  Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. , 1993, Brain : a journal of neurology.

[433]  J. Jankovic,et al.  Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations. , 2006, Archives of neurology.

[434]  S. Tsuji,et al.  Novel mutations, pseudo‐dominant inheritance, and possible familial affects in patients with autosomal recessive juvenile parkinsonism , 2000, Annals of neurology.

[435]  M. Vidailhet,et al.  Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. , 2011, Human molecular genetics.

[436]  A. Durr,et al.  The sepiapterin reductase gene region reveals association in the PARK3 locus: analysis of familial and sporadic Parkinson’s disease in European populations , 2005, Journal of Medical Genetics.

[437]  S. Lindquist,et al.  α-Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity , 2009, Nature Genetics.

[438]  E. Sidransky,et al.  Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA) , 2008, Human mutation.

[439]  C. Marsden,et al.  Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease , 1990, Journal of neurochemistry.

[440]  M. Farrer,et al.  alpha-Synuclein and Parkinson disease susceptibility. , 2007, Neurology.

[441]  J. Downward,et al.  The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1 , 2007, Nature Cell Biology.

[442]  Yi Zhao,et al.  LRRK2 R1628P increases risk of Parkinson’s disease: replication evidence , 2008, Human Genetics.

[443]  P. Lockhart,et al.  Parkin Protects against the Toxicity Associated with Mutant α-Synuclein Proteasome Dysfunction Selectively Affects Catecholaminergic Neurons , 2002, Neuron.

[444]  M. Glicksman,et al.  Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities. , 2010, Biochemistry.

[445]  Daniel R. Scoles,et al.  The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI. , 2003, Human molecular genetics.

[446]  T. Iwatsubo [alpha-Synuclein and familial Parkinson's disease]. , 1999, No to shinkei = Brain and nerve.

[447]  M. Beal,et al.  PINK1 Defect Causes Mitochondrial Dysfunction, Proteasomal Deficit and α-Synuclein Aggregation in Cell Culture Models of Parkinson's Disease , 2009, PloS one.

[448]  A. Whitworth,et al.  Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss , 2009, Nature Neuroscience.

[449]  M. Farrer,et al.  α-Synuclein and Parkinson disease susceptibility , 2007, Neurology.

[450]  He-Jin Lee,et al.  Clearance of α-Synuclein Oligomeric Intermediates via the Lysosomal Degradation Pathway , 2004, The Journal of Neuroscience.

[451]  J. Lee,et al.  Rhomboid-7 and HtrA 2 / Omi act in a common pathway with the Parkinson ’ s disease factors Pink 1 and Parkin , 2022 .

[452]  M. Cookson,et al.  Parkin-mediated ubiquitination regulates phospholipase C-γ1 , 2008, Journal of cellular and molecular medicine.

[453]  J. Nutt,et al.  LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. , 2006, American journal of human genetics.

[454]  Peter T. Lansbury,et al.  Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct , 2001, Science.

[455]  N. Wood,et al.  PINK1 (PARK6) associated Parkinson disease in Ireland , 2004, Neurology.

[456]  Sonja W. Scholz,et al.  Parkin and PINK1 mutations in early-onset Parkinson’s disease: comprehensive screening in publicly available cases and control , 2009, Journal of Medical Genetics.

[457]  Daniel Sage,et al.  Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. , 2008, Human molecular genetics.

[458]  Colin A. Johnson,et al.  PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron , 2006, Nature Genetics.

[459]  R A Crowther,et al.  alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[460]  A. Brookes,et al.  The parkin gene S/N167 polymorphism in Australian Parkinson's disease patients and controls. , 2001, Parkinsonism & related disorders.

[461]  J. Nutt,et al.  Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease , 2010, Nature Genetics.

[462]  J. Ridet,et al.  alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[463]  A. Destée,et al.  LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans. , 2007, Archives of neurology.

[464]  M. Cookson,et al.  Parkin deficiency disrupts calcium homeostasis by modulating phospholipase C signalling , 2009, The FEBS journal.

[465]  K. Marder,et al.  Distribution, type, and origin of Parkin mutations: Review and case studies , 2004, Movement disorders : official journal of the Movement Disorder Society.

[466]  A. Dürr,et al.  LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century. , 2005, American journal of human genetics.

[467]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[468]  C. Chien,et al.  The utility F-box for protein destruction , 2008, Cellular and Molecular Life Sciences.

[469]  Y. Agid,et al.  Coding polymorphisms in the parkin gene and susceptibility to Parkinson disease. , 2003, Archives of neurology.

[470]  P. Lansbury,et al.  The UCH-L1 Gene Encodes Two Opposing Enzymatic Activities that Affect α-Synuclein Degradation and Parkinson's Disease Susceptibility , 2002, Cell.

[471]  Takashi Uehara,et al.  Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[472]  P. Lansbury,et al.  Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. , 2001, Biochemistry.

[473]  M. Ehlers,et al.  Pruning and loss of excitatory synapses by the parkin ubiquitin ligase , 2008, Proceedings of the National Academy of Sciences.

[474]  N. Bonini,et al.  DJ-1 is critical for mitochondrial function and rescues PINK1 loss of function , 2010, Proceedings of the National Academy of Sciences.

[475]  PINK1 Protects against Oxidative Stress by Phosphorylating Mitochondrial Chaperone TRAP1 , 2007, PLoS biology.

[476]  A. Sidhu,et al.  Does α‐synuclein modulate dopaminergic synaptic content and tone at the synapse? , 2004 .

[477]  T. Meitinger,et al.  Multiple regions of α‐synuclein are associated with Parkinson's disease , 2005, Annals of neurology.

[478]  J. C. Greene,et al.  Immune responses , 2004 .

[479]  B. Ghetti,et al.  Ubiquitination of α-Synuclein in Lewy Bodies Is a Pathological Event Not Associated with Impairment of Proteasome Function* , 2003, Journal of Biological Chemistry.

[480]  T. Dawson,et al.  Conditional transgenic mice expressing C-terminally truncated human α-synuclein (αSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons , 2009, Molecular Neurodegeneration.

[481]  N. Hattori,et al.  A LRRK2 G2019S mutation carrier from Turkey shares the Japanese haplotype , 2009, neurogenetics.

[482]  M. Farrer,et al.  Spinocerebellar ataxia type 2 with parkinsonism in ethnic Chinese , 2000, Neurology.

[483]  A. Samii,et al.  Identification and haplotype analysis of LRRK2 G2019S in Japanese patients with Parkinson disease , 2006, Neurology.

[484]  B. E. Staveley,et al.  parkin counteracts symptoms in a Drosophila model of Parkinson's disease , 2004, BMC Neuroscience.

[485]  M. Farrer,et al.  ATP13A2 variability in Parkinson disease , 2009, Human mutation.

[486]  M. Beal,et al.  Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[487]  A. H. V. Schapira,et al.  MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.

[488]  David S. Park,et al.  BAG5 Inhibits Parkin and Enhances Dopaminergic Neuron Degeneration , 2004, Neuron.

[489]  A. Singleton,et al.  Association of α‐synuclein Rep1 polymorphism and Parkinson's disease: Influence of Rep1 on age at onset , 2006, Movement disorders : official journal of the Movement Disorder Society.

[490]  C. Marsden,et al.  Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. , 1992, Annals of neurology.

[491]  R. Barker,et al.  A case of late onset sporadic Parkinson's disease with an A53T mutation in alpha-synuclein. , 2005, Journal of neurology, neurosurgery, and psychiatry.

[492]  Jeffrey H Kordower,et al.  Proteasome inhibition and Parkinson's disease modeling , 2006, Annals of neurology.

[493]  R. Szargel,et al.  Monoubiquitylation of α-Synuclein by Seven in Absentia Homolog (SIAH) Promotes Its Aggregation in Dopaminergic Cells* , 2008, Journal of Biological Chemistry.

[494]  J. Troncoso,et al.  S-Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function , 2004, Science.

[495]  M. Mena,et al.  Differential effects of l‐DOPA on monoamine metabolism, cell survival and glutathione production in midbrain neuronal‐enriched cultures from parkin knockout and wild‐type mice , 2005, Journal of neurochemistry.

[496]  V. Mylius,et al.  The prevalence of the G2019S and R1441C/G/H mutations in LRRK2 in German patients with Parkinson’s disease , 2008, European journal of neurology.

[497]  O. Combarros,et al.  LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson's disease , 2006, Neuroscience Letters.

[498]  E. Katunina,et al.  [Epidemiology of Parkinson's disease]. , 2013, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[499]  M. Farrer,et al.  Genomic investigation of α‐synuclein multiplication and parkinsonism , 2008, Annals of neurology.

[500]  P. Silburn,et al.  Screening PARK genes for mutations in early-onset Parkinson's disease patients from Queensland, Australia. , 2009, Parkinsonism & related disorders.

[501]  F. Giorgino,et al.  Two Novel Proteins That Are Linked to Insulin-like Growth Factor (IGF-I) Receptors by the Grb10 Adapter and Modulate IGF-I Signaling* , 2003, Journal of Biological Chemistry.

[502]  A. Schapira,et al.  Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. , 2010, Human molecular genetics.

[503]  V. Nair Activation of p53 signaling initiates apoptotic death in a cellular model of Parkinson’s disease , 2006, Apoptosis.

[504]  A. Letai,et al.  Parkin selectively alters the intrinsic threshold for mitochondrial cytochrome c release. , 2009, Human molecular genetics.

[505]  J. Cooper,et al.  Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease , 1998, Annals of neurology.

[506]  R. Schwab,et al.  COHORT ANALYSIS OF PARKINSON'S SYNDROME: EVIDENCE FOR A SINGLE ETIOLOGY RELATED TO SUBCLINICAL INFECTION ABOUT 1920. , 1963, Journal of chronic diseases.

[507]  A. Bentivoglio,et al.  GIGYF2 variants are not associated with Parkinson's disease in Italy , 2009, Movement disorders : official journal of the Movement Disorder Society.

[508]  J. Holton,et al.  PINK1 protein in normal human brain and Parkinson's disease. , 2006, Brain : a journal of neurology.

[509]  K. Jellinger,et al.  Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease , 1994, Neuroscience Letters.

[510]  W. Xia,et al.  Dimerization of Parkinson's disease-causing DJ-1 and formation of high molecular weight complexes in human brain , 2004, Molecular and Cellular Neuroscience.

[511]  C. Ross,et al.  Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. , 2001, Human molecular genetics.

[512]  Jian Feng,et al.  Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. , 2004, Human molecular genetics.

[513]  J. Cooper,et al.  Silencing of PINK1 Expression Affects Mitochondrial DNA and Oxidative Phosphorylation in DOPAMINERGIC Cells , 2009, PloS one.

[514]  K. Xia,et al.  Novel GIGYF2 gene variants in patients with Parkinson's disease in Chinese population , 2010, Neuroscience Letters.

[515]  H. Budka,et al.  Accumulation of HtrA2/Omi in Neuronal and Glial Inclusions in Brains With &agr;-Synucleinopathies , 2008, Journal of neuropathology and experimental neurology.

[516]  Douglas C. Miller,et al.  A large kindred with autosomal dominant Parkinson's disease , 1990, Annals of neurology.

[517]  C. Waters,et al.  Autosomal dominant Lewy body parkinsonism in a four‐generation family , 1994, Annals of neurology.

[518]  David S. Park,et al.  Leucine-Rich Repeat Kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease. , 2009, Human molecular genetics.

[519]  A. Quattrone,et al.  LRRK2 G6055A mutation in Italian patients with familial or sporadic Parkinson’s disease , 2007, Clinical genetics.

[520]  Peter T. Lansbury,et al.  Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy , 2004, Science.

[521]  C. Chu,et al.  Role of autophagy in G2019S‐LRRK2‐associated neurite shortening in differentiated SH‐SY5Y cells , 2008, Journal of neurochemistry.

[522]  F. Lee,et al.  Parkin Disrupts the α-Synuclein/Dopamine Transporter Interaction: Consequences Toward Dopamine-induced Toxicity , 2007, Journal of Molecular Neuroscience.

[523]  Min Liu,et al.  Parkin Ubiquitinates Drp1 for Proteasome-dependent Degradation , 2011, The Journal of Biological Chemistry.

[524]  G. Halliday,et al.  An inflammatory review of Parkinson’s disease , 2002, Progress in Neurobiology.

[525]  Sonja W. Scholz,et al.  Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data , 2006, The Lancet Neurology.

[526]  D. Rubinsztein,et al.  Loss of PINK1 Function Affects Development and Results in Neurodegeneration in Zebrafish , 2008, The Journal of Neuroscience.

[527]  C Büchel,et al.  Morphometric fingerprint of asymptomatic Parkin and PINK1 mutation carriers in the basal ganglia , 2007, Neurology.

[528]  Y. Itoyama,et al.  Serine 129 Phosphorylation of α-Synuclein Induces Unfolded Protein Response-mediated Cell Death* , 2008, Journal of Biological Chemistry.

[529]  J. Allman,et al.  Neuropathology provides clues to the pathophysiology of Gaucher disease. , 2004, Molecular genetics and metabolism.

[530]  J. Burgunder,et al.  LRRK2 R1628P variant is a risk factor of Parkinson's disease among Han‐Chinese from mainland China , 2009, Movement disorders : official journal of the Movement Disorder Society.

[531]  P. Pollak,et al.  LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. , 2006, The New England journal of medicine.

[532]  Janel O. Johnson,et al.  Comprehensive Screening of a North American Parkinson’s Disease Cohort for LRRK2 Mutation , 2007, Neurodegenerative Diseases.

[533]  Y. Agid,et al.  Parkin mutations are frequent in patients with isolated early-onset parkinsonism. , 2003, Brain : a journal of neurology.

[534]  T. Zhang,et al.  The GIGYF2 variants are not associated with Parkinson's disease in the mainland Chinese population. , 2010, Parkinsonism & related disorders.

[535]  A Dürr,et al.  Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. , 2004, Lancet.

[536]  J. Cappell,et al.  Tiagabine-induced nonconvulsive status epilepticus in an adolescent without epilepsy , 2006, Neurology.

[537]  A. Singleton,et al.  Sequencing analysis of OMI/HTRA2 shows previously reported pathogenic mutations in neurologically normal controls. , 2008, Human molecular genetics.

[538]  A. Brice,et al.  Neurophysiological evidence of corticospinal tract abnormality in patients with Parkin mutations , 2006, Journal of Neurology.

[539]  P. Jenner,et al.  Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats , 2006, Annals of neurology.

[540]  G. Tocchini-Valentini,et al.  Altered dopamine signaling and MPTP resistance in mice lacking the Parkinson's disease-associated GPR37/parkin-associated endothelin-like receptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[541]  J. Epplen,et al.  The LRRK2 gene in Parkinson’s disease: mutation screening in patients from Germany , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[542]  S. Papapetropoulos,et al.  Clinical characteristics of the alpha‐synuclein mutation (G209A)‐associated Parkinson's disease in comparison with other forms of familial Parkinson's disease in Greece , 2003, European journal of neurology.

[543]  M. Farrer,et al.  A Swedish family with de novo alpha-synuclein A53T mutation: evidence for early cortical dysfunction. , 2009, Parkinsonism & related disorders.

[544]  A. Singleton,et al.  Parkinson's Disease and Low Frequency Alleles Found Together Throughout LRRK2 , 2009, Annals of human genetics.

[545]  T. Iwatsubo,et al.  Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[546]  Mohamad Saad,et al.  Genome-wide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson's disease in the European population. , 2011, Human molecular genetics.

[547]  Hongjun Song,et al.  Accumulation of the Authentic Parkin Substrate Aminoacyl-tRNA Synthetase Cofactor, p38/JTV-1, Leads to Catecholaminergic Cell Death , 2005, The Journal of Neuroscience.

[548]  E. Hirsch,et al.  The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration. , 2003, Human molecular genetics.

[549]  Sonja Hess,et al.  Broad activation of the ubiquitin–proteasome system by Parkin is critical for mitophagy , 2011, Human molecular genetics.

[550]  Thorsten Schmidt,et al.  Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis , 2004, The Lancet Neurology.

[551]  P. Damier,et al.  Follow-up study of the GIGYF2 gene in French families with Parkinson's disease , 2010, Neurobiology of Aging.

[552]  M. Farrer,et al.  Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain. , 2007, Parkinsonism & related disorders.

[553]  H. Liu Alpha-synuclein and Parkinson disease* , 2007 .

[554]  A. Sidhu,et al.  Modulation of dopamine transporter function by α‐synuclein is altered by impairment of cell adhesion and by induction of oxidative stress , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[555]  Mark A. Wilson,et al.  Formation of a Stabilized Cysteine Sulfinic Acid Is Critical for the Mitochondrial Function of the Parkinsonism Protein DJ-1* , 2009, Journal of Biological Chemistry.

[556]  Cao Li,et al.  The prevalence of LRRK2 Gly2385Arg variant in Chinese Han population with Parkinson's disease. , 2007, Movement disorders : official journal of the Movement Disorder Society.

[557]  E. Schon,et al.  The kinase domain of mitochondrial PINK1 faces the cytoplasm , 2008, Proceedings of the National Academy of Sciences.

[558]  J. Stockman Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease , 2011 .

[559]  P. Lockhart,et al.  DJ-1 mutations are a rare cause of recessively inherited early onset parkinsonism mediated by loss of protein function , 2004, Journal of Medical Genetics.

[560]  A. Pisani,et al.  Enhanced sensitivity to group II mGlu receptor activation at corticostriatal synapses in mice lacking the familial parkinsonism-linked genes PINK1 or Parkin , 2009, Experimental Neurology.

[561]  Normand L. Frigon,et al.  Polo-like Kinase 2 (PLK2) Phosphorylates α-Synuclein at Serine 129 in Central Nervous System*S⃞ , 2009, Journal of Biological Chemistry.

[562]  K. Lim,et al.  Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. , 2007, Human molecular genetics.

[563]  N. Hattori,et al.  Autosomal recessive early-onset parkinsonism with diurnal fluctuation: clinicopathologic characteristics and molecular genetic identification , 2000, Brain and Development.

[564]  M. Umeda,et al.  Proteasome Inhibitor Does Not Enhance MPTP Neurotoxicity in Mice , 2008, Cellular and Molecular Neurobiology.

[565]  Yusuke Nakamura,et al.  Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease , 2009, Nature Genetics.

[566]  J. Trojanowski,et al.  Neuroinflammation and Oxidation/Nitration of α-Synuclein Linked to Dopaminergic Neurodegeneration , 2008, The Journal of Neuroscience.

[567]  Nir Giladi,et al.  Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset , 2008, Neurology.

[568]  M. Farrer,et al.  Multiple alpha‐synuclein gene polymorphisms are associated with Parkinson’s disease in a Norwegian population , 2008, Acta neurologica Scandinavica.

[569]  M. Ban,et al.  Tau and α‐synuclein in susceptibility to, and dementia in, Parkinson's disease , 2007 .

[570]  N. Hattori,et al.  Clinicogenetic study of PINK1 mutations in autosomal recessive early-onset parkinsonism , 2005, Neurology.

[571]  M. Polymeropoulos,et al.  Mapping of a Gene for Parkinson's Disease to Chromosome 4q21-q23 , 1996, Science.

[572]  R. Hilker,et al.  Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers , 2005, Annals of neurology.

[573]  R. Takahashi,et al.  Phosphorylation of 4E‐BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila , 2008, The EMBO journal.

[574]  D. Dickson,et al.  Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson’s disease , 2008, Acta Neuropathologica.

[575]  N. Brüggemann,et al.  Frequency of heterozygous Parkin mutations in healthy subjects: need for careful prospective follow-up examination of mutation carriers. , 2009, Parkinsonism & related disorders.

[576]  David W. Miller,et al.  Kinase activity is required for the toxic effects of mutant LRRK2/dardarin , 2006, Neurobiology of Disease.

[577]  N. Hattori,et al.  Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin‐like domain , 2003, EMBO reports.

[578]  R. J. Kelleher,et al.  Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of α-synuclein, and apoptotic cell death in aged mice , 2010, Proceedings of the National Academy of Sciences.

[579]  J. Trojanowski,et al.  Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. , 2002, Acta neuropathologica.

[580]  E. Beutler,et al.  Hematologically important mutations: Gaucher disease. , 2005, Blood cells, molecules & diseases.

[581]  Steven P Gygi,et al.  Certain Pairs of Ubiquitin-conjugating Enzymes (E2s) and Ubiquitin-Protein Ligases (E3s) Synthesize Nondegradable Forked Ubiquitin Chains Containing All Possible Isopeptide Linkages* , 2007, Journal of Biological Chemistry.

[582]  R. Palmiter,et al.  Parkin-mediated K63-linked polyubiquitination targets misfolded DJ-1 to aggresomes via binding to HDAC6 , 2007, The Journal of cell biology.

[583]  P. Kempster,et al.  A new look at James Parkinson's Essay on the Shaking Palsy , 2007, Neurology.

[584]  D. Elstein,et al.  The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. , 2005, The New England journal of medicine.

[585]  A. Torroni,et al.  Mitochondrial oxidative phosphorylation defects in parkinson's disease , 1991, Annals of neurology.

[586]  A. Lang,et al.  Deciphering the role of heterozygous mutations in genes associated with parkinsonism , 2007, The Lancet Neurology.

[587]  W. Oertel,et al.  Alpha‐synuclein and Parkinson's disease: Implications from the screening of more than 1,900 patients , 2005, Movement disorders : official journal of the Movement Disorder Society.

[588]  J. Perlmutter,et al.  Association of alpha-synuclein gene haplotypes with Parkinson's disease. , 2007, Parkinsonism & Related Disorders.

[589]  F. Brancati,et al.  Whole gene deletion and splicing mutations expand the PINK1 genotypic spectrum , 2007, Human mutation.

[590]  Timothy Lynch,et al.  Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. , 2005, American journal of human genetics.

[591]  N. Hattori,et al.  Parkin cleaves intracellular alpha-synuclein inclusions via the activation of calpain. , 2003, The Journal of biological chemistry.

[592]  R. Youle,et al.  Parkin is recruited selectively to impaired mitochondria and promotes their autophagy , 2008, The Journal of cell biology.

[593]  A. Brice,et al.  Parkin occurs in a stable, non-covalent, ∼110-kDa complex in brain , 2008, The European journal of neuroscience.

[594]  Jie Shen,et al.  Absence of nigral degeneration in aged parkin/DJ‐1/PINK1 triple knockout mice , 2009, Journal of neurochemistry.

[595]  D. Price,et al.  Parkinson's Disease α-Synuclein Transgenic Mice Develop Neuronal Mitochondrial Degeneration and Cell Death , 2006, The Journal of Neuroscience.

[596]  D. D. Di Monte The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? , 2003, The Lancet. Neurology.

[597]  Bertram Müller-Myhsok,et al.  Mutations in the pantothenate kinase gene PANK2 are not associated with Parkinson disease , 2005, Neuroscience Letters.

[598]  E. Valente,et al.  Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. , 2005, Human molecular genetics.

[599]  Wolfgang Wurst,et al.  Loss of Parkin or PINK1 Function Increases Drp1-dependent Mitochondrial Fragmentation* , 2009, The Journal of Biological Chemistry.

[600]  Gianluigi Forloni,et al.  DJ-1 Modulates α-Synuclein Aggregation State in a Cellular Model of Oxidative Stress: Relevance for Parkinson's Disease and Involvement of HSP70 , 2008, PloS one.

[601]  K. Wada,et al.  Aberrant Interaction between Parkinson Disease-associated Mutant UCH-L1 and the Lysosomal Receptor for Chaperone-mediated Autophagy* , 2008, Journal of Biological Chemistry.

[602]  A. Singleton,et al.  Analysis of Nigerians with Apparently Sporadic Parkinson Disease for Mutations in LRRK2, PRKN and ATXN3 , 2008, PloS one.

[603]  A. Abeliovich,et al.  DJ-1 Is a Redox-Dependent Molecular Chaperone That Inhibits α-Synuclein Aggregate Formation , 2004, PLoS biology.

[604]  Georg Auburger,et al.  The ubiquitin pathway in Parkinson's disease , 1998, Nature.

[605]  Y. Agid,et al.  Screening for DJ-1 mutations in early onset autosomal recessive parkinsonism , 2003, Neurology.

[606]  C. Geula,et al.  Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons , 2006, Nature Genetics.

[607]  P. Lansbury,et al.  Phosphorylation at Ser-129 but Not the Phosphomimics S129E/D Inhibits the Fibrillation of α-Synuclein* , 2008, Journal of Biological Chemistry.

[608]  M. Farrer,et al.  Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism. , 2009, Parkinsonism & related disorders.

[609]  A Hofman,et al.  Prevalence of Parkinson's disease in the elderly , 1995, Neurology.

[610]  J. C. Greene,et al.  Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[611]  L. Seeberger,et al.  Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease , 2003, Neurology.

[612]  Jurg Ott,et al.  Genome‐wide autozygosity mapping in human populations , 2009, Genetic epidemiology.

[613]  Tom A. Rapoport,et al.  The AAA ATPase Cdc48/p97 and its partners transport proteins from the ER into the cytosol , 2001, Nature.

[614]  R A Crowther,et al.  Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. , 1998, Neuroscience letters.

[615]  Karl Herholz,et al.  The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans , 2002, Neuroscience Letters.

[616]  A. Abeliovich,et al.  The Familial Parkinsonism Gene LRRK2 Regulates Neurite Process Morphology , 2006, Neuron.

[617]  Ying Wang,et al.  Lack of association between ATP13A2 Ala746Thr variant and Parkinson's disease in Han population of mainland China , 2010, Neuroscience Letters.

[618]  D. Maraganore,et al.  Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990 , 1999, Neurology.

[619]  J. Xie,et al.  Parkinson's Disease Brain Mitochondrial Complex I Has Oxidatively Damaged Subunits and Is Functionally Impaired and Misassembled , 2006, The Journal of Neuroscience.

[620]  D. Benson,et al.  Alzheimer's disease and Parkinson's disease , 1988, Neurology.

[621]  W. Hwu,et al.  Mutation analysis of Gaucher disease patients in Taiwan: high prevalence of the RecNciI and L444P mutations. , 2006, Blood cells, molecules & diseases.

[622]  J. Y. Kim,et al.  Does hereditary hemochromatosis influence the age of onset of Huntington's disease? , 2010, Movement disorders : official journal of the Movement Disorder Society.

[623]  He-Jin Lee,et al.  Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[624]  J. Jankovic,et al.  Lrrk2 R1441G-related Parkinson’s disease: evidence of a common founding event in the seventh century in Northern Spain , 2009, neurogenetics.

[625]  M. Cookson,et al.  Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase , 2008, Proceedings of the National Academy of Sciences.

[626]  Philippe Amouyel,et al.  Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. , 2004, Lancet.

[627]  K. Sobczak,et al.  CAG Repeats Containing CAA Interruptions Form Branched Hairpin Structures in Spinocerebellar Ataxia Type 2 Transcripts* , 2005, Journal of Biological Chemistry.

[628]  M. Farrer,et al.  Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. , 2007, Parkinsonism & related disorders.

[629]  A. Singleton,et al.  Lack of replication of association between GIGYF2 variants and Parkinson disease. , 2008, Human molecular genetics.

[630]  A. Destée,et al.  Molecular analyses of the LRRK2 gene in European and North African autosomal dominant Parkinson’s disease , 2009, Journal of Medical Genetics.

[631]  J. Feldon,et al.  Dopamine-dependent neurodegeneration in rats induced by viral vector-mediated overexpression of the parkin target protein, CDCrel-1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[632]  R. Takahashi,et al.  Pael‐R is accumulated in Lewy bodies of Parkinson's disease , 2004, Annals of neurology.

[633]  T. Dawson,et al.  Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[634]  R. Ramsay,et al.  Mechanism of the neurotoxicity of MPTP , 1990, FEBS letters.

[635]  G. Lopez,et al.  The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism , 2009, Movement disorders : official journal of the Movement Disorder Society.

[636]  A. Schapira Mitochondria in the aetiology and pathogenesis of Parkinson's disease , 2008, The Lancet Neurology.

[637]  Yi Zhao,et al.  Genetic analysis of DJ-1 in a cohort Parkinson’s disease patients of different ethnicity , 2004, Neuroscience Letters.

[638]  T. Gillis,et al.  Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. , 2006, Archives of neurology.

[639]  R. Marconi,et al.  ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease , 2007, Neurology.

[640]  C. Culmsee,et al.  Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling. , 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[641]  D. Cordato,et al.  Genetics and Parkinson’s disease , 2004, Journal of Clinical Neuroscience.

[642]  M. Farrer,et al.  Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries , 2006, Movement disorders : official journal of the Movement Disorder Society.

[643]  A. Whitworth,et al.  PINK1 cleavage at position A103 by the mitochondrial protease PARL , 2010, Human molecular genetics.

[644]  Nicholas W Wood,et al.  A common LRRK2 mutation in idiopathic Parkinson's disease , 2005, The Lancet.

[645]  A. Varrone,et al.  PINK1 homozygous W437X mutation in a patient with apparent dominant transmission of parkinsonism , 2006, Movement disorders : official journal of the Movement Disorder Society.

[646]  M. Farrer,et al.  Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication , 2007, Neurology.

[647]  J Q Trojanowski,et al.  A Hydrophobic Stretch of 12 Amino Acid Residues in the Middle of α-Synuclein Is Essential for Filament Assembly* , 2001, The Journal of Biological Chemistry.

[648]  N. Quinn,et al.  The role of pathogenic DJ‐1 mutations in Parkinson's disease , 2003, Annals of neurology.

[649]  O. Riess,et al.  Detection of Parkin (PARK2) and DJ1 (PARK7) mutations in early‐onset Parkinson disease: Parkin mutation frequency depends on ethnic origin of patients , 2004, Human mutation.

[650]  Changan Jiang,et al.  Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin , 2006, Nature.

[651]  Akihiko Iwai,et al.  The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system , 1995, Neuron.

[652]  K. McNaught,et al.  Proteasomal function is impaired in substantia nigra in Parkinson's disease , 2001, Neuroscience Letters.

[653]  K. Xia,et al.  Analysis of SCA2 and SCA3/MJD repeats in Parkinson's disease in mainland China: Genetic, clinical, and positron emission tomography findings , 2009, Movement disorders : official journal of the Movement Disorder Society.

[654]  S. Murayama,et al.  Alpha‐synucleinopathy is associated with spinocerebellar ataxia type 2 with Parkinsonism , 2008 .

[655]  David F. Clayton,et al.  The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease , 1998, Trends in Neurosciences.

[656]  U. Muthane,et al.  Absence/rarity of commonly reported LRRK2 mutations in Indian Parkinson's disease patients , 2006, Neuroscience Letters.

[657]  M. Farrer,et al.  Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population , 2006, Neurology.

[658]  Matti Pirinen,et al.  Dissection of the genetics of Parkinson's disease identifies an additional association 5′ of SNCA and multiple associated haplotypes at 17q21 , 2010, Human molecular genetics.

[659]  J. Trojanowski,et al.  Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. , 2002, Science.

[660]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[661]  D. Eliezer,et al.  Conformational properties of alpha-synuclein in its free and lipid-associated states. , 2001, Journal of molecular biology.

[662]  I. Guella,et al.  Mutational screening and zebrafish functional analysis of GIGYF2 as a Parkinson-disease gene , 2009, Neurobiology of Aging.

[663]  B. Oostra,et al.  A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson’s disease risk in Taiwan , 2006, Neurogenetics.

[664]  N. Mizushima,et al.  Parkin Mediates Proteasome-dependent Protein Degradation and Rupture of the Outer Mitochondrial Membrane*♦ , 2011, The Journal of Biological Chemistry.

[665]  C. Fusco,et al.  Characterization of a Novel Human Serine Protease That Has Extensive Homology to Bacterial Heat Shock Endoprotease HtrA and Is Regulated by Kidney Ischemia* , 2000, The Journal of Biological Chemistry.

[666]  R. Ridley,et al.  Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. , 2007, Brain : a journal of neurology.

[667]  H. Niznik,et al.  Direct binding and functional coupling of α-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[668]  A. Lees,et al.  A clinicopathologic study of 100 cases of Parkinson's disease. , 1993, Archives of neurology.

[669]  J. Trojanowski,et al.  Glucocerebrosidase mutations are an important risk factor for Lewy body disorders , 2006, Neurology.

[670]  E. Bertini,et al.  Neurodegeneration associated with genetic defects in phospholipase A2 , 2008, Neurology.

[671]  H. Inoko,et al.  Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease. , 2006, Human molecular genetics.

[672]  A. Lang,et al.  Genetic association study of PINK1 coding polymorphisms in Parkinson's disease , 2004, Neuroscience Letters.

[673]  Nir Giladi,et al.  Ashkenazi Parkinson’s disease patients with the LRRK2 G2019S mutation share a common founder dating from the second to fifth centuries , 2009, neurogenetics.

[674]  Shawn K. Westaway,et al.  A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome , 2001, Nature Genetics.

[675]  Nigel J. Cairns,et al.  Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies , 1998, Neuroscience Letters.

[676]  Nikolaus R. McFarland,et al.  &agr;-Synuclein S129 Phosphorylation Mutants Do Not Alter Nigrostriatal Toxicity in a Rat Model of Parkinson Disease , 2009, Journal of neuropathology and experimental neurology.

[677]  P. Lockhart,et al.  Functional association of the parkin gene promoter with idiopathic Parkinson's disease. , 2002, Human molecular genetics.

[678]  R. Krüger,et al.  Haploinsufficiency at the alpha-synuclein gene underlies phenotypic severity in familial Parkinson's disease. , 2003, Brain : a journal of neurology.

[679]  D. Perl,et al.  Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease , 2004, Annals of neurology.

[680]  Santiago Canals,et al.  Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. , 2003, Human molecular genetics.

[681]  T. Noda,et al.  A subdomain of the endoplasmic reticulum forms a cradle for autophagosome formation , 2009, Nature Cell Biology.

[682]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[683]  M. Farrer,et al.  The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients , 2005, Neuroscience Letters.

[684]  L. Seeberger,et al.  Significant linkage of Parkinson disease to chromosome 2q36-37. , 2003, American journal of human genetics.

[685]  M. Cookson,et al.  Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking. , 2009, Biochemistry.

[686]  R. Youle,et al.  Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin , 2010, The Journal of cell biology.

[687]  A. Destée,et al.  Are interrupted SCA2 CAG repeat expansions responsible for parkinsonism? , 2007, Neurology.

[688]  Andrew Lees,et al.  Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.

[689]  Rachel Levy,et al.  PLA2G6 mutation underlies infantile neuroaxonal dystrophy. , 2006, American journal of human genetics.

[690]  G. Mardon,et al.  Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress , 2004, Development.

[691]  Y. Hong,et al.  Parkin Suppresses c-Jun N-terminal kinase-induced cell death via transriptional regulation in Drosophila , 2010, Molecules and cells.

[692]  Mostafa Ronaghi,et al.  Whole genome survey of coding SNPs reveals a reproducible pathway determinant of Parkinson disease , 2008, Human mutation.

[693]  N. Wood,et al.  Mitochondrial function and morphology are impaired in parkin‐mutant fibroblasts , 2008, Annals of neurology.

[694]  E. Masliah,et al.  Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[695]  K. Gwinn‐Hardy,et al.  Genetic testing in spinocerebellar ataxia in Taiwan: expansions of trinucleotide repeats in SCA8 and SCA17 are associated with typical Parkinson's disease , 2004, Clinical genetics.

[696]  Philippe Vernier,et al.  Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse? , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[697]  P. Allen,et al.  Generalized mitochondrial dysfunction in Parkinson's disease detected by magnetic resonance spectroscopy of muscle , 1995, Neurology.

[698]  E. Tolosa,et al.  LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance. , 2006, Archives of neurology.

[699]  R. Nicoll,et al.  Increased Expression of α-Synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering after Endocytosis , 2010, Neuron.

[700]  Ying Wang,et al.  GIGYF2 Asn56Ser mutation is rare in Chinese Parkinson's disease patients , 2009, Neuroscience Letters.

[701]  Y. Agid,et al.  G2019S LRRK2 mutation in French and North African families with Parkinson's disease , 2005, Annals of neurology.

[702]  Nobutaka Hattori,et al.  Ubiquitination of a New Form of α-Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease , 2001, Science.

[703]  Reidun Torp,et al.  Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. , 2005, Human molecular genetics.

[704]  T. Hirokawa,et al.  Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. , 2003, Biochemical and biophysical research communications.

[705]  S. Karlsson,et al.  Murine models of acute neuronopathic Gaucher disease , 2007, Proceedings of the National Academy of Sciences.

[706]  M. Feany,et al.  Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. , 2005, Nature neuroscience.

[707]  A. Antonini,et al.  Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation , 2007, Movement disorders : official journal of the Movement Disorder Society.

[708]  A. Dürr,et al.  Deletion of the parkin and PACRG gene promoter in early‐onset parkinsonism , 2007, Human mutation.

[709]  B. Oostra,et al.  LRRK2 MUTATION ANALYSIS IN PARKINSON DISEASE FAMILIES WITH EVIDENCE OF LINKAGE TO PARK8 , 2008, Neurology.

[710]  A. Brice,et al.  Pseudo-dominant inheritance and exon 2 triplication in a family with parkin gene mutations , 2001, Neurology.

[711]  M. Farrer,et al.  Distinctive neuropathology revealed by α-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p , 2000, Acta Neuropathologica.

[712]  Irene Litvan,et al.  Lrrk2 and Lewy body disease , 2006, Annals of neurology.

[713]  C. Ross,et al.  Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[714]  C. Ki,et al.  The Ala53Thr mutation in the alpha-synuclein gene in a Korean family with Parkinson disease. , 2007, Clinical genetics.

[715]  D. Selkoe,et al.  Pink1 Parkinson mutations, the Cdc37/Hsp90 chaperones and Parkin all influence the maturation or subcellular distribution of Pink1. , 2008, Human molecular genetics.

[716]  L. Serpell,et al.  Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[717]  C. Marsden,et al.  Mitochondrial function in Parkinson's disease , 1992, Annals of neurology.

[718]  T. Chase,et al.  Degradation of α-Synuclein by Proteasome* , 1999, The Journal of Biological Chemistry.

[719]  M. Breteler,et al.  Epidemiology of Parkinson's disease , 2006, The Lancet Neurology.

[720]  K. Marder,et al.  Case-control study of the parkin gene in early-onset Parkinson disease. , 2006, Archives of neurology.

[721]  S. Tsuji,et al.  A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2–q13.1 , 2002, Annals of neurology.

[722]  D. Hernandez,et al.  Lewy bodies and parkinsonism in families with parkin mutations , 2001, Annals of neurology.

[723]  T. Dawson,et al.  Parkin mediates the degradation‐independent ubiquitination of Hsp70 , 2008, Journal of neurochemistry.

[724]  C. Chu A pivotal role for PINK1 and autophagy in mitochondrial quality control: implications for Parkinson disease. , 2010, Human molecular genetics.

[725]  C. Ross,et al.  Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. , 2005, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[726]  Y. Imai,et al.  Parkin Suppresses Unfolded Protein Stress-induced Cell Death through Its E3 Ubiquitin-protein Ligase Activity* , 2000, The Journal of Biological Chemistry.

[727]  P. Matthews,et al.  LRRK2 Gly2019Ser penetrance in Arab–Berber patients from Tunisia: a case-control genetic study , 2008, The Lancet Neurology.

[728]  C. Ross,et al.  α-Synuclein Phosphorylation Enhances Eosinophilic Cytoplasmic Inclusion Formation in SH-SY5Y Cells , 2005, The Journal of Neuroscience.

[729]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[730]  John Q. Trojanowski,et al.  Induction of α-Synuclein Aggregation by Intracellular Nitrative Insult , 2001, The Journal of Neuroscience.

[731]  N. Hattori,et al.  PARK9-LINKED PARKINSONISM IN EASTERN ASIA: MUTATION DETECTION IN ATP13A2 AND CLINICAL PHENOTYPE , 2008, Neurology.

[732]  A. Dürr,et al.  Clinical and molecular advances in autosomal dominant cerebellar ataxias: from genotype to phenotype and physiopathology , 2000, European Journal of Human Genetics.

[733]  A. Singleton,et al.  Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls , 2008, Human mutation.

[734]  P. Lockhart,et al.  Parkin genetics: one model for Parkinson's disease. , 2004, Human molecular genetics.

[735]  A. Björklund,et al.  Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of α-Synuclein in the Nigrostriatal System , 2002, The Journal of Neuroscience.

[736]  H. Niznik,et al.  Direct binding and functional coupling of α‐synuclein to the dopamine transporters accelerate dopamine‐induced apoptosis , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[737]  M. Farrer,et al.  Familial genes in sporadic disease: Common variants of α-synuclein gene associate with Parkinson's disease , 2007, Mechanisms of Ageing and Development.

[738]  P. Kapahi,et al.  Loss-of-Function Analysis Suggests That Omi/HtrA2 Is Not an Essential Component of the pink1/parkin Pathway In Vivo , 2008, The Journal of Neuroscience.

[739]  Aldo Quattrone,et al.  Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. , 2006, JAMA.

[740]  V. Mok,et al.  LRRK2 Gly2385Arg mutation and clinical features in a Chinese population with early-onset Parkinson’s disease compared to late-onset patients , 2008, Journal of Neural Transmission.

[741]  Min Liu,et al.  Parkin Regulates Eg5 Expression by Hsp70 Ubiquitination-dependent Inactivation of c-Jun NH2-terminal Kinase* , 2008, Journal of Biological Chemistry.

[742]  T. Gasser,et al.  Independent occurrence of I2020T mutation in the kinase domain of the leucine rich repeat kinase 2 gene in Japanese and German Parkinson's disease families , 2007, Neuroscience Letters.

[743]  Sunhong Kim,et al.  Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin , 2006, Nature.

[744]  Christian Haass,et al.  Pathological properties of the Parkinson’s disease-associated protein DJ-1 in α-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick’s disease , 2004, Acta Neuropathologica.

[745]  J. Kordower,et al.  Age-associated increases of α-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? , 2007, Neurobiology of Disease.

[746]  J. Nutt,et al.  Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[747]  R. Krüger,et al.  Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7) , 2004, Human mutation.

[748]  D. Eliezer,et al.  Effects of Parkinson's disease-linked mutations on the structure of lipid-associated alpha-synuclein. , 2004, Biochemistry.

[749]  L. Scorrano,et al.  Mitofusin 2 tethers endoplasmic reticulum to mitochondria , 2008, Nature.

[750]  S. Minoshima,et al.  Immunohistochemical and subcellular localization of parkin protein: Absence of protein in autosomal recessive juvenile parkinsonism patients , 1999, Annals of neurology.

[751]  M. Farrer,et al.  Genetic variation of Omi/HtrA2 and Parkinson's disease. , 2008, Parkinsonism & related disorders.

[752]  R. Youle,et al.  Parkin-induced mitophagy in the pathogenesis of Parkinson disease , 2009, Autophagy.

[753]  David W. Miller,et al.  L166P Mutant DJ-1, Causative for Recessive Parkinson's Disease, Is Degraded through the Ubiquitin-Proteasome System* , 2003, Journal of Biological Chemistry.

[754]  R. Palmiter,et al.  Novel Monoclonal Antibodies Demonstrate Biochemical Variation of Brain Parkin with Age* , 2003, Journal of Biological Chemistry.

[755]  Bernardino Ghetti,et al.  Pathological Changes in Dopaminergic Nerve Cells of the Substantia Nigra and Olfactory Bulb in Mice Transgenic for Truncated Human α-Synuclein(1–120): Implications for Lewy Body Disorders , 2006, The Journal of Neuroscience.

[756]  S. Srinivasula,et al.  Loss of Omi mitochondrial protease activity causes the neuromuscular disorder of mnd2 mutant mice , 2003, Nature.

[757]  A. Antonini,et al.  alpha-Synuclein multiplication analysis in Italian familial Parkinson disease. , 2010, Parkinsonism & related disorders.

[758]  N. Hattori,et al.  Leucine-Rich Repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population , 2007, Neuroreport.